

1 **Title: Phase 1 trial of a Candidate Recombinant Virus-Like Particle Vaccine for Covid-19**
2 **Disease Produced in Plants**

3

4 **Authors:** Brian J Ward^{1,2}, Philippe Gobeil¹, Annie Séguin¹, Judith Atkins¹, Iohann Boulay¹
5 Pierre-Yves Charbonneau¹, Manon Couture¹, Marc-André D'Aoust¹, Jiwanjeet
6 Dhaliwall¹, Carolyn Finkle¹, Karen Hager¹, Asif Mahmood¹, Alexander Makarkov¹,
7 Matthew Cheng², Stéphane Pillet¹, Patricia Schimke¹, Sylvie St-Martin¹, Sonia
8 Trépanier¹, Nathalie Landry^{1*}

9

10 ¹ Medicago Inc., 1020 route de l'Église office 600, Québec, QC, Canada, G1V 3V9

11 ² Research Institute of the McGill University Health Centre, 1001 Decarie St, Montreal, QC
12 H4A 3J1

13 * *Corresponding author:*

14 Nathalie Landry

15 1020 Route de l'Église, Bureau 600

16 Québec, Qc, Canada

17 G1V 3V9

18 Tel. 418 658 93931

19 Fax. 418 658 6699

20 Landryn@medicago.com

21

22

23 **Keywords**

24 SARS-CoV-2, Covid-19 vaccine, virus-like particles, *Nicotiana benthamiana*, *Agrobacterium*
25 *tumefaciens*, safety and immunogenicity, cell-mediated immunity,

26

27

28 Other Material Study Protocols (1), Statistical Analysis Plans (1) Supplemental
29 material (1)

30

31

32 **Research In Context**

33

34 **Evidence before this study**

35 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was recognized as the
36 causative agent of COVID-19 in early 2020. Since that time, >150 candidate vaccines are
37 reported to be under development of which 47 have entered clinical trials
38 (<https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines>
39 accessed Nov 4, 2020). No vaccine to prevent COVID-19 has been licensed yet for either
40 emergency or general use in North America or Europe. We searched PubMed for research
41 articles published between July 2019 and November 4, 2020, using the terms “SARS-CoV-2”,
42 “vaccine”, “clinical trial” OR “human”, AND “phase”. The same terms were used to search
43 ClinTrials.gov. No language restrictions were applied. We identified 10 peer-reviewed studies,
44 describing phase 1 or 1/2 trials using a range of novel (eg: RNA, DNA, non-replicating virus
45 vectored) and more traditional vaccine approaches (eg: inactivated virus or recombinant protein
46 ± adjuvants). None of these candidate vaccines was produced in plants. These reports
47 demonstrate that several different vaccination strategies (typically delivered in two doses 14-28
48 days apart) are capable of eliciting neutralizing antibody responses. In several cases, vaccine-
49 induced cellular responses against SARS-COV-2 antigens - predominantly the spike (S) protein
50 - can also be demonstrated. Although local and systemic adverse events following vaccination
51 have varied between reports, the trials published to date suggest that each of these candidate
52 vaccines is well-tolerated in the context of an evolving pandemic.

53

54 **Added value of this study**

55 We report the results of the first clinical study of CoVLP, a virus-like particle (VLP) vaccine
56 that is produced by transient transfection of *Nicotiana benthamiana* plants. These VLPs
57 spontaneously assemble at the plant cell membrane and display SARS-COV-2 trimers of
58 stabilized pre-fusion S protein on their surface. The vaccine was administered as two
59 intramuscular doses 21 days apart at three dose levels (S protein content 3.75, 7.5 or 15µg)
60 alone or adjuvanted with either CpG1018 or AS03. All formulations were well-tolerated
61 although both adjuvants increased reactogenicity. Humoral (anti-S IgG and neutralizing
62 antibodies) as well as cellular responses (IFNγ and IL4 ELISpots) were detectable in almost all

63 subjects who received adjuvanted formulations 21 days after the second dose at all COVLP
64 dose levels. Both antibody and cellular responses were highest in subjects who received AS03-
65 adjuvanted formulations. Even at the lowest dose level (3.75µg), the neutralizing antibody titers
66 21 days after the second dose in subjects who received the AS03-adjuvanted vaccine were 10-
67 50-fold higher than those seen in subjects recovering from COVID-19 infection.

68

69 **Implications of all the available evidence**

70 Effective vaccines against SARS-CoV-2 are urgently needed to reduce the burden of disease
71 and contribute to ending the global pandemic. Although no immune correlates for SARS-CoV-
72 2 have been defined, it is likely that both arms of the immune system contribute to protection.
73 After two doses of CoVLP (3.75µg+AS03), strong humoral and cellular responses were
74 induced supporting the further clinical development of this vaccine.

75

76 **Longer Abstract**

77 **Background:** The stabilized prefusion form of the SARS-CoV-2 spike protein is produced by
78 transient expression in *Nicotiana benthamiana*. The trimeric spike glycoproteins are displayed
79 at the surface of self-assembling Virus-Like-Particles that mimic the shape and the size of the
80 virus. The candidate vaccine (CoVLP) administered alone or with AS03 or CpG1018
81 adjuvants was evaluated in a Phase 1 trial in healthy adults. (ClinicalTrials.gov number
82 NCT04450004)

83

84 **Methods:** The study was a randomized, partially-blinded, prime-boost 21 days apart, dose-
85 escalation Phase 1 study intended to assess the safety, tolerability, and immunogenicity of
86 CoVLP at three dose levels (3.75 µg, 7.5 µg, and 15 µg) unadjuvanted or adjuvanted with
87 either CpG 1018 or AS03 in 180 SARS-CoV-2 seronegative healthy adults 18 to 55 years of
88 age. Enrollment was staggered for dose-escalation. At each dose level, the vaccine was initially
89 administered to a small number of subjects. Vaccination of the remaining subjects at the same
90 dose level and the next higher vaccine dose level was administered with approval of an
91 Independent Data Monitoring Committee (IDMC). The same procedure was followed for the
92 second vaccine administration. Monitoring of safety signals was performed throughout the
93 study with pre-determined pausing/stopping rules if there was clear evidence of harmful effects
94 such as severe adverse events (AEs) related to the treatment. The primary endpoints were the
95 safety and tolerability of the vaccine after each dose and the immunogenicity as assessed by
96 neutralizing antibody responses assessed using a vesicular stomatitis virus (VSV) pseudovirion
97 assay and interferon-gamma (IFN-γ) and interleukin-4 (IL-4) ELISpot assays at Days 0, 21 and
98 42. Secondary endpoints were anti-spike antibody responses by ELISA and neutralizing
99 antibodies measured by live virus plaque reduction neutralization test (PRNT) assay at Days 0,
100 21 and 42 and immunogenicity with additional safety and immunogenicity endpoints planned
101 for 6-months following the last vaccination. The anti-spike and neutralizing antibody responses
102 were compared with 23 convalescent serum samples from symptomatic Covid-19 patients. We
103 performed a primary analysis at day 42.

104

105 **Results:** A total of 180 subjects (102 females: 78 males: average 34.3 years) were recruited to
106 the study and interim safety and immunogenicity data up to day 42 after the first dose are
107 reported here. There was no obvious CoVLP dose effect in safety outcomes for any of the
108 formulations tested and all formulations were generally well-tolerated. Most solicited local and
109 systemic AEs were mild-moderate and transient. Reactogenicity was increased in all adjuvanted

110 formulations and was generally highest in the CoVLP+AS03 groups. Local and systemic
111 adverse events were reported with similar frequency after the first and second doses in subjects
112 who received either CoVLP alone or CoVLP+CpG1018 but increased in both frequency and
113 severity after the second dose in the CoVLP+AS03 groups. CoVLP alone only elicited a weak
114 total anti-spike IgG response at the highest dose level and little-to-no neutralization antibody
115 response, even after the second dose. Cellular responses in the CoVLP alone groups (IFN γ and
116 IL-4) were detectable after the second dose but were still only marginally above background
117 levels. The addition of either adjuvant substantially increased both antibody and cellular
118 responses at most CoVLP dose levels and changes were most pronounced after the second
119 dose. However, a substantial neutralizing antibody response after the first dose was only seen in
120 all CoVLP+AS03 groups. After the second dose, both total anti-spike IgG and neutralizing
121 antibody titers in the CoVLP+AS03 groups were higher than those in the CoVLP+CpG1018
122 groups. The antibody titers achieved were either similar to (CoVLP+CpG1018) or at least 10-
123 times higher (CoVLP+AS03) than those seen in convalescent plasma. Administration of
124 CoVLP with either adjuvant also significantly increased the cellular responses. After 2 doses,
125 both IFN- γ and IL-4 responses were significantly increased in the CoVLP+CpG1018 groups. In
126 the CoVLP+AS03 groups, significant increases in the cellular responses were observed after
127 the first dose while IFN- γ and IL-4 increased further in both magnitude and number of subjects
128 responding after the second dose. Again, the cellular responses in the CoVLP+AS03 groups
129 were higher than those seen in the CoVLP+CpG1018 groups.

130

131 **Conclusion:** These data demonstrate that CoVLP administered with either CpG1018 or AS03
132 has a safety profile similar to other candidate vaccines for SARS-CoV-2. When administered
133 with either AS03 or CpG1018, several of the CoVLP dose levels elicited strong humoral and T
134 cell responses after the second dose. When administered with AS03, even the 3.75 μ g CoVLP
135 dose elicited neutralizing antibody titers that were ~10-times higher than those observed in
136 individuals recovering from Covid-19 as well as consistent and balanced IFN- γ and IL-4
137 responses. Although many CoVLP formulations were immunogenic, in the absence of
138 established correlates of protection and given the advantages of dose-sparing in the context of
139 the on-going pandemic, these findings suggest that CoVLP (3.75 μ g)+AS03 has a good
140 benefit/risk ratio and support the transition of this formulation to studies in expanded
141 populations and to efficacy evaluations

142

143

144 **Shorter Abstract (Word count: 242)**

145 **Background:** Virus-like particles (VLP) displaying recombinant SARS-CoV-2 spike protein
146 trimers were produced by transient expression in *Nicotiana benthamiana*. This candidate
147 vaccine (CoVLP) was evaluated in healthy adults 18-55 years of age alone or with AS03 or
148 CpG1018 (NCT04450004).

149

150 **Methods:** This randomized, partially-blinded, two-dose, dose-escalation study assessed
151 CoVLP (3.75, 7.5 or 15 µg/dose) administered intramuscularly alone or with CpG1018 or
152 AS03 in SARS-CoV-2 seronegative adults (18-55 years). Primary endpoints of safety and
153 immunogenicity are reported to day 42. Neutralizing antibodies (NtAb) were assessed using a
154 VSV pseudovirus assay and cellular responses by ELISpot (IFN γ , IL-4).

155

156 **Results:** 180 subjects (avg.34.3yrs) were recruited. All formulations were well-tolerated but
157 adjuvants increased reactogenicity. Adverse events were highest in the CoVLP+AS03 groups
158 and increased in frequency/severity after dose two. CoVLP alone elicited weak humoral
159 responses but modest cellular responses were detectable after dose two. Both adjuvants
160 increased immunogenicity significantly, particularly after dose two. A significant NtAb
161 response after dose one was only seen in CoVLP+AS03 groups. The vaccine dose had little
162 impact on levels of NtAb responses achieved in the CoVLP+AS03 groups. Both adjuvants also
163 increased IFN γ and IL-4 responses but these cellular responses also tended to be highest in the
164 AS03-adjuvanted groups.

165

166 **Conclusion:** CoVLP \pm adjuvants was well-tolerated. Several adjuvanted formulations
167 elicited strong humoral and T cell responses after dose 2. Even at the lowest CoVLP+AS03
168 dose, NtAb titers were \sim 10-times higher than in convalescent serum with a balanced IFN γ and
169 IL-4 response. These findings support-the transition of CoVLP (3.75µg+AS03) to further
170 clinical evaluation.

171

172 **Introduction (Word count: 458)**

173

174 A novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
175 jumped across a species barrier in China in late 2019^{1,2} and spread rapidly around the globe
176 leading to the World Health Organization's declaration of a pandemic on March 11, 2020³. As
177 of October 11th, 2020, more than 37 million cases of Covid-19 have been reported with >1
178 million deaths⁴. Although many therapeutic strategies has been tried^{5,6,7}, the current options
179 remain limited in both number and efficacy. Simultaneously, there has been a massive global
180 effort to develop vaccines. This effort was primed to some extent by prior experience with other
181 highly pathogenic human coronaviruses, SARS and MERS⁸ and the far-sighted efforts of the
182 Coalition for Epidemic Preparedness Innovations (CEPI) to develop vaccines for a 'short-list'
183 of pathogens with pandemic potential⁹. At the time of writing, >150 vaccine candidates have
184 been announced, >30 are in clinical trials and a small number have been authorized for limited
185 use in some countries¹⁰. These candidates are based on a wide range of traditional and novel
186 platforms including mRNA, DNA, inactivated virus, live viral vectors, recombinant proteins,
187 peptides, and virus-like particles (VLPs)^{11,12}. No vaccine has been approved for general use yet
188 in North America.

189

190 Adding to the complexity of this situation is the facts that no correlate of immunity has been
191 defined for any highly pathogenic coronavirus^{13,14} and that such correlates might differ
192 between vaccines¹⁵. Nonetheless, a protective role for both humoral and cell-mediated
193 immunity against coronaviruses has been suggested^{16,17}. Antibody responses against the spike
194 (S) protein have the potential to protect from infection¹⁸⁻²⁰ and convalescent plasma with high
195 titers of anti-S antibody have therapeutic benefit in selected patients^{7,21}. However, a substantial
196 proportion of people who develop Covid-19 fail to generate antibodies, and data from the
197 SARS-CoV-1 outbreak of 2002–2003²² and the current pandemic suggest that antibody
198 responses can be short-lived, disappearing within months of infection in some patients²³. In
199 contrast, T cell immunity may be critical for recovery from Covid-19^{24,25} and was shown to
200 persist for up to 11 years after SARS-CoV-1 infection²⁶. T cells can provide substantial
201 protection in animal models of highly pathogenic coronavirus infection.

202

203 We report here the results of a Phase 1 study initiated in July 2020 evaluating the safety,
204 tolerability and immunogenicity of two doses, 21-days apart of 3.75, 7.5 or 15 µg of a virus-
205 like-particle vaccine candidate for Covid-19 produced in plants (hereafter called CoVLP). This

206 recombinant platform has been used to produce hemagglutinin (HA)-bearing VLP vaccines for
207 avian (monovalent) and seasonal (quadrivalent) influenza that induce balanced humoral and T
208 cell responses²⁸⁻³¹. The CoVLP vaccine was administered alone or with AS03 or CpG1018
209 adjuvants in healthy adults 18-55 years of age.

210

211 **Methods (Word count: 687)**

212

213 *The CoVLP Vaccine and Adjuvants*

214 The full-length S glycoprotein of SARS-CoV-2, strain hCoV-19/USA/CA2/2020,
215 corresponding in sequence to nucleotides 21563 to 25384 from EPI_ISL_406036 in GISAID
216 database (<https://www.gisaid.org/>) was expressed in *Nicotiana benthamiana* plants as
217 previously described³². The S protein was modified with R667G, R668S and R670S
218 substitutions at the S1/S2 cleavage site to increase stability, and K971P and V972P
219 substitutions to stabilize the protein in prefusion conformation. The signal peptide was replaced
220 with a plant gene signal peptide and the transmembrane domain (TM) and cytoplasmic tail
221 (CT) of S protein was also replaced with TM/CT from Influenza H5 A/Indonesia/5/2005 to
222 increase VLP assembly and budding. The self-assembled VLPs bearing S protein trimers were
223 isolated from the plant matrix and subsequently purified using a process similar to that
224 described for the influenza vaccine candidates²⁸.

225

226 The AS03 adjuvant, an oil-in-water emulsion containing tocopherol and squalene, was
227 supplied by GlaxoSmithKline. The CpG 1018 adjuvant, composed of cytosine
228 phosphoguanine (CpG) motifs, was supplied by Dynavax. The CoVLP vaccine and
229 adjuvants were mixed immediately prior to administration

230

231 *Study design*

232 The Phase 1 study was conducted at two sites in Quebec City and Montreal (Protocol available
233 in Supplemental Material). At screening, health status was assessed by medical history,
234 physical exam and clinical laboratory findings including detection of antibodies to SARS-CoV-
235 2 (ElecSys: Roche Diagnostics). Healthy seronegative subjects 18-55 years of age who met all
236 inclusion criteria and no exclusion criterion were enrolled and randomized into nine groups.
237 Randomised subjects received two doses, 21 days apart of CoVLP at doses of 3.75, 7.5 or 15
238 µg unadjuvanted or adjuvanted with AS03 or CpG1018. The participants and the personnel
239 collecting the safety information and testing laboratories remained blinded to treatment

240 allocation. On Day 0 (D0: pre-first dose), D21 (pre-second dose) and D42 (post second dose),
241 serum and peripheral blood mononuclear cells (PBMC) were processed for immune outcomes
242 as described previously ²⁸.

243

244 *Safety*

245 For details of safety monitoring, see the Protocol in Suppl. Materials. Briefly, enrollment was
246 staggered for dose-escalation with sentinel subjects at each dose level (n=6) and independent
247 data monitoring committee (IDMC) review of D3 safety data at 10% and 30% recruitment
248 before each dose acceleration. The same process was followed for the second vaccine
249 administration. Monitoring of safety signals was performed throughout the study (Suppl
250 Material: pp 2). Solicited adverse events (AEs) were assessed by the subjects as Grade 1 to 4
251 (mild, moderate, severe, or potentially life-threatening). Unsolicited AEs, and AEs leading to
252 subject withdrawal were collected up to D21 after each vaccination. All serious AEs (SAE),
253 Adverse Events of Special Interest (AESIs), and pregnancies will be collected for 6 months.
254 Potential cases of vaccine enhanced disease (VED), hypersensitivity and potential immune-
255 mediated diseases (pIMDs) are being monitored throughout the study (see Suppl. Material: pp
256 7, Tables S2, S3).

257

258 *Immunogenicity assessments*

259 The primary immunological outcomes were neutralizing antibody (NAb) responses measured
260 using a VSV pseudovirion assay (Nexelis Inc, Laval, QC) and IFN γ and IL-4 cellular responses
261 measured by ELISpot at D0, 21 and 42. Secondary immunological outcomes were total anti-
262 spike IgG responses by ELISA and NAb responses by plaque reduction neutralization test
263 (PRNT: Vismedri S.r.l., Siena, Italy) Details of these assays are provided in the Suppl.
264 Material (pp 3-5).

265

266 Antibody responses were compared with those of individuals who had recovered from PCR-
267 confirmed Covid-19 obtained from Solomon Park (Burien, WA)), Sanguine BioSciences
268 (Sherman Oaks, CA) and M Cheng (McGill University Health Center, Montreal, Quebec). The
269 severity of disease ranged from mild-moderate (n=23) to severe/critical (n=11) (Suppl.
270 Material: Table S1 for patient characteristics: pp 6).

271

272 *Analysis Populations and Statistical Analysis Plan*

273

274 Overall, 180 healthy SATRS-COV-2 seronegative male and female subjects 18 to 55 years of
275 age were randomized in a 1:1:1:1:1:1:1:1:1 ratio into nine treatment groups. The sample size
276 made it possible to perform the initial evaluation of the vaccine immunogenicity and detect
277 major differences in rates of AEs between groups. The sample size was not large enough to
278 detect all types, including less frequent or rare, AEs.

279

280 The analyses of all immunogenicity endpoints were based on the Per Protocol set (PP) and are
281 described in the Statistical Analysis Plan provided as Supplementary Material.

282

283 **Results (Word count: 1090)**

284 *Demographic and baseline clinical characteristics*

285

286 Participant demographics are presented in Table 1 and subject disposition up to D42 is
287 presented in Table 2 and in Suppl. Materials: Fig. S1: pp. 19. More women (56.7%) than men
288 (43.3%) were enrolled but the female:male ratio was the same for each CoVLP dose level and
289 in each of the overall groups (unadjuvanted CoVLP, CoVLP+AS03, CoVLP+CpG1018).

290 Subjects were mostly White (96%) with 2% each of Black or African American and Asian
291 subjects. The average age was 34.3 years. A total of 180 subjects received the first dose of
292 vaccine and 178 subjects received both doses. See Fig. S1 in Suppl. Materials for details.

293

294 *Safety*

295 Reactogenicity for all formulations was generally mild in severity (Figure 1) and of short
296 duration. Both adjuvants increased the frequency of reported AEs. The frequency and severity
297 of AEs were similar after the first and second doses in the unadjuvanted CoVLP and
298 CoVLP+CpG1018 groups but increased after the second dose in subjects who received AS03-
299 adjuvanted formulations. Details of solicited AEs and TEAEs by treatment group are provided
300 in Suppl. Materials: Tables S4-S9).

301

302 There was no consistent impact of CoVLP dose level on safety outcomes in any group. After
303 the first dose, 74.3% of participants reported >1 solicited AE, 66.5% reporting a local reaction

304 and 39.7% reporting >1 systemic event. Pain at the injection site was the most common local
305 reaction (66.5%) while headache and fatigue were reported by 25.7% and 20.7% respectively.
306 The incidence of headache and fatigue were generally higher in the adjuvanted treatment
307 groups. AEs were mostly mild-moderate Grade 1-2) and only one Grade 3 report of fatigue
308 that started the evening following vaccination and resolved the same day. After the second
309 dose, 68.5% of participants reported >1 solicited AE, 62.9% reporting a local reaction and
310 47.8% reporting >1 systemic event. Pain at the injection site was again the most reported local
311 reaction (61.2%) while headache and fatigue were reported by 33.1% and 33.1% respectively.
312 Again, most symptoms were mild but there were more moderate AEs after the second dose.
313 Nine Grade 3 solicited severe AEs (fatigue, redness at injection site, swelling at injection site,
314 feeling of general discomfort or uneasiness) were reported in 6 subjects after the second dose.
315 All but one of the Grade 3 reactions were reported by subjects who received AS03-adjuvanted
316 formulations. One Grade 3 reaction occurred after the second dose in the CoVLP (7.5
317 µg)+CpG1018 group. All Grade 3 AEs resolved in one to four days. No clinically significant
318 lab abnormalities were reported after any dose. No SAEs, AESIs or pregnancy
319 exposures have been reported at the time of writing.

320

321 *Immunogenicity: Antibody Response*

322 A small number of subjects (12/180; 6.7%) had detectable pre-existing antibodies for the spike
323 protein in one or more of the assays used. As illustrated in Figure 2, unadjuvanted CoVLP
324 elicited no detectable antibody response after the first dose and humoral responses after even
325 the second dose were modest and inconsistent. Although a minor dose-effect for the
326 unadjuvanted CoVLP was seen on the anti-spike IgG response (ELISA) after the second
327 vaccination, the responses in the two NAb assays remained low and variable even at the highest
328 dose tested. Both adjuvants had a significant impact on antibody responses at all dose levels.
329 Although there was no convincing effect of increasing CoVLP dose for either adjuvant, there
330 was a trend towards increasing consistency of response in the CoVLP+CpG1018 groups at the
331 higher CoVLP doses (ie: a greater response and a larger proportion of subjects responding).
332 Although both adjuvants elicited modest IgG titers after the first dose, only the groups that
333 received COVLP+AS03 formulations mounted significant NAb responses at D21 (36/60; 60%)
334 and across all dose levels (ie: overall GMT of 33.3 in the pseudovirus assay). Both adjuvants
335 induced more robust responses after the second dose with the large majority of subjects at all
336 dose levels mounting a ≥ 4 -fold rise in total IgG (117/118; 99.1%) and in both NAb assays

337 (105/112; 93.8% in the pseudovirion assay and 106/116; 91.3% in the PRNT). At all dose
338 levels, both anti-spike IgG and pseudovirion NAb titers at D42 were 10- to 50- fold higher in
339 subjects who had received AS03-adjuvanted formulations compared to those who had received
340 CpG1018-adjuvanted formulations. For example, after the second CoVLP(3.75 µg) dose, the
341 GMTs in the PRNT were 7.2 for CoVLP alone, 56.6 for CoVLP+CpG1018 and 811.3 for
342 CoVLP+AS03. Overall, the levels of NAb induced in the groups that received two doses of
343 CoVLP with an adjuvant were either similar to (CoVLP+CpG1018) or substantially greater
344 (CoVLP+AS03) than those seen in subjects 3-4 weeks after recovering from natural Covid-19
345 infection. Details of serologic response results by treatment group are presented in Suppl.
346 Materials: Tables S10-S12.

347

348 *Correlation between Neutralizing Antibody Assays*

349 There was a strong correlation between the VSV pseudovirion neutralization assay and the
350 PRNT for responses in all groups: $r=0.85$ ($p < 0.0001$) after the first (Figure 3A) and $r = 0.68$
351 ($p < 0.0001$) second vaccinations (Figure 3B).

352

353 *Immunogenicity: T Cell Response*

354 As illustrated in Figure 4, the IFN γ and IL-4 responses in PBMC (ELISpot) elicited by CoVLP
355 \pm adjuvants were more variable than the antibody responses. A substantial minority of subjects
356 in all groups had what appeared to be pre-existing IFN γ responses to the S protein peptide pool
357 that were, in some subjects, substantial (ie: >200 spots)³³. Although low level ‘background’ IL-
358 4 activity was seen in a small number of subjects, these responses were close to the limit of
359 detection of the assay used (generally <10 spots). Unlike antibody responses, CoVLP alone was
360 able to induce a substantial IFN γ response and, to a lesser extent, IL-4 response in many
361 subjects after the second doses at all dose levels but that was most consistently seen at the
362 highest dose (CoVLP 15µg). Both adjuvants generally increased IFN γ and IL-4 responses
363 above background levels after the first dose that were further and substantially increased in
364 magnitude and consistency by the second dose. Compared to unadjuvanted CoVLP, IFN γ
365 responses were slightly higher and IL-4 responses were slightly lower in the CpG1018-
366 adjuvanted groups but most of these differences did not reach statistical significance. Once
367 again, the IFN γ and IL-4 responses to the CoVLP+AS03 formulations at all dose levels were 10
368 to 50-fold higher than those seen in the equivalent CoVLP+CpG1018 groups. For example, at

369 the 3.75 μ g dose level: median IFN γ and IL-4 responses at D42 were 628 and 445 in the
370 CoVLP+AS03 group and 49 and 4 in the CoVLP+CpG1018 group. Details of cellular response
371 results by treatment group are provided in Suppl. Materials: Tables S13 - S14.

372

373 **Discussion (Word count: 1223)**

374

375 This phase 1 study was designed to select the CoVLP formulation (ie: dose level \pm
376 adjuvant) and the number of doses needed to generate a consistent immune response in
377 healthy adults with an acceptable safety profile. Although unadjuvanted CoVLP had the
378 lowest reactogenicity and was recognized by the immune system after the second dose,
379 the immune responses measured (i.e.:anti-spike IgG, NAb, IFN γ and IL-4 ELISpots)
380 were generally modest. These observations are consistent with studies of plant-derived
381 VLP vaccines bearing HA trimers of avian influenza strains^{30,34} in which serologic and
382 T cell responses were observed with unadjuvanted formulations at doses >15 μ g but
383 were seen at lower doses when administered with an oil-in-water adjuvant (GLA-SE)³⁴.
384 Although we observed no dose effect with unadjuvanted CoVLP for antibody or
385 cellular responses, it is possible that higher doses of unadjuvanted CoVLP would have
386 induced stronger responses. However, two different adjuvants were incorporated into
387 this study because of their potential to induce more robust responses at a lower CoVLP
388 dose (ie: dose-sparing).

389

390 While sharing some characteristics (ie: documented immune enhancement, large safety
391 databases, previously licensed)³⁵⁻³⁸, the inclusion of both CpG1018 and AS03
392 permitted us to ask multiple questions about CoVLP performance simultaneously. In
393 the case of CpG1018, by targeting the innate toll-like receptor 9 we hoped that both
394 arms of the adaptive immune system would be engaged with induction of humoral and
395 cellular responses³⁹. Although the mechanism of action of oil-in-water adjuvants like
396 AS03 is still under active investigation⁴⁰, the combination of squalene and tocopherol
397 (vitamin E) in AS03 has also been shown to enhance both humoral and cellular
398 responses with several different vaccine antigens^{41,42}.

399

400 In the current study, the adjuvants performed as expected with enhancement of humoral
401 and cellular responses to the S protein and in promoting responses at lower CoVLP
402 doses. In both dose-sparing and enhancing immune responses, AS03 appeared to be
403 more effective than CpG1018. For example, a substantial minority of the subjects who
404 received even the lowest dose of CoVLP+AS03 (3.75 µg) mounted detectable NAb
405 responses after the first dose but no similar response was seen in the CpG1018-
406 adjuvanted groups. Furthermore, the anti-spike IgG and NAb responses were
407 consistently higher at all dose levels in the AS03-adjuvanted groups compared to the
408 CpG1018-adjuvanted groups although differences did not reach statistical significance
409 at higher doses of CoVLP. The humoral response to the AS03-adjuvanted formulations
410 demonstrated no CoVLP dose effect, particularly after the second dose. Overall, the
411 differences between unadjuvanted and adjuvanted formulations and between the two
412 adjuvants were less pronounced for Th1-type cell-mediated responses than for antibody
413 responses. Nonetheless, IFN γ responses to adjuvanted formulations were consistently
414 higher at most dose levels than responses to CoVLP alone, particularly after the second
415 dose. Overall, IFN γ responses were strongest in the AS03-adjuvanted groups,
416 particularly at lower CoVLP dose levels. Of course, it is possible that the IFN γ
417 responses observed were mediated in part by other cells (eg: NK or CD8 T cells),
418 since the ELISpot assay captures cell-mediated responses indiscriminately⁴⁴. Additional
419 flow cytometry evaluations are warranted to characterize the phenotype of these
420 cellular responses more comprehensively and in particular, to better understand the
421 relative contribution of CD4 T cells to the observed responses. The IL-4 response was
422 also consistently higher in the AS03-adjuvanted groups compared to the unadjuvanted
423 or CpG1018-adjuvanted groups. In the AS03-adjuvanted groups, the IL4 response was
424 10-fold lower than the IFN γ responses after the first dose but rose to near equivalence
425 with the second dose suggesting a balanced Th1- and Th2-type response.

426

427 It is noteworthy that a substantial proportion of the subjects in this study appeared to
428 have pre-existing IFN γ responses to the S protein peptide pool used for PBMC

429 restimulation. Such cross-reactive T cell memory, possibly due to prior exposure to
430 common human coronaviruses has been seen in 40-60% of adults and may provide
431 some protection against highly pathogenic strains³³. Prior exposure to circulating
432 coronaviruses may also explain the small number of subjects in this study (6.7%) who
433 were ‘seronegative’ at screening based upon a commercial N-based ELISA but who
434 were sero-positive at D0 in our assays targeting the S protein.

435

436 Together, these immune outcome data suggest that CoVLP alone can elicit both
437 humoral and cellular responses that are Th1-biased to some extent and that this pattern
438 of response is reinforced when adjuvanted with CpG1018. In contrast, when CoVLP is
439 adjuvanted with AS03, the response was faster and more balanced with evidence of
440 both Th1- and Th2-type activation. Although Th2-deviated responses have been
441 implicated in VED (e.g.: early RSV vaccine)⁴⁵ and are a theoretical risk for vaccines
442 targeting pathogenic coronaviruses⁴⁶, the engagement of T cells is also critical for B-
443 cell maturation and the induction of strong and durable antibody responses^{47,48}.

444

445 The safety profile of CoVLP alone was relatively benign at all dose levels but, as
446 expected, both the frequency and the intensity of local and systemic AEs was increased
447 with either adjuvant. Compared to the first dose, the frequency of Grade 2 or Grade 3
448 AEs also increased after the second dose in all groups that received adjuvanted
449 formulations. All AEs reported, regardless of dose level, adjuvant or initial intensity,
450 were transient and resolved rapidly. Although one subject did not receive a second dose
451 of vaccine due to a grade 3 AE (per Protocol), no subject voluntarily withdrew from the
452 study due to any AE/SAE. Overall, the reactogenicity of the adjuvanted CoVLP
453 formulations was similar to that reported for other candidate SARS-CoV-2 vaccines in
454 early-phase clinical studies. Although hypersensitivity to plant material is a theoretical
455 risk with any plant-derived product, no subject in the current study had an allergic-type
456 reaction, consistent with Medicigo’s safety database of >14,000 subjects who have
457 received one or two doses of plant-derived influenza vaccine candidates⁴⁹.

458

459 Like any early-phase clinical trial, this study has several limitations beyond the obvious
460 concern regarding small group size when testing multiple dose levels and formulations
461 (n=20/group). For comparisons between formulations however, the small group risk
462 was mitigated by the fact that results across the three CoVLP dose levels were highly
463 consistent (n=60 for CoVLP alone or with each adjuvant). Another obvious concern is
464 the relatively limited range of immune response parameters available at the time of
465 writing. Although the data presented herein provide a ‘first look’ at the immune
466 response induced by the different formulations, the immune profiles will be further
467 investigated in the coming months. Finally, like all other early-phase trials, our study
468 assessed only the short-term (day 42) response to vaccination and the durability of
469 these responses will only become apparent as subjects are followed for longer periods
470 of time. However, based on the robust high antibody and balanced cellular responses to
471 the adjuvanted CoVLP formulations and our previous experience with plant-derived
472 VLP vaccines targeting influenza, we anticipate that the CoVLP-induced responses are
473 likely to last for at least 6 months^{30, 50}.

474

475 In conclusion, this first trial of CoVLP alone or adjuvanted with either CpG1018 or
476 AS03 suggests that our plant-derived candidate vaccine is well-tolerated and
477 immunogenic. Its immunogenicity, particularly at low doses, is dramatically enhanced
478 by the presence of an adjuvant. Based upon the totality of non-clinical and clinical
479 results available and the obvious advantages of dose-sparing in a pandemic, a two-dose
480 schedule of CoVLP at 3.75 µg/dose adjuvanted with AS03 will be carried forward into
481 further studies planned for Canada, the USA and other countries.

482

483 References

484

- 485 1. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in
486 China. *N Engl J Med* 2020;382:1708-20.
- 487 2. Zhu F-C, Guan X-H, Li Y-H, et al. Immunogenicity and safety of a recombinant
488 adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a
489 randomised, double-blind, placebo-controlled, phase 2 trial. *The Lancet* 2020;396:479-88.
- 490 3. World Health Organization, WHO Director-General's opening remarks at the media
491 briefing on COVID-19 - 11 March 2020. 2020. at [https://www.who.int/dg/speeches/detail/who-](https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020)
492 [director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020.](https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020))
- 493 4. World Health Organization, Coronavirus disease (COVID-19) Weekly Epidemiological
494 Update. 2020. at [https://www.who.int/docs/default-source/coronaviruse/situation-](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20201012-weekly-epi-update-9.pdf)
495 [reports/20201012-weekly-epi-update-9.pdf.](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20201012-weekly-epi-update-9.pdf))
- 496 5. Santos J, Brierley S, Gandhi MJ, Cohen MA, Moschella PC, Declan ABL. Repurposing
497 Therapeutics for Potential Treatment of SARS-CoV-2: A Review. *Viruses* 2020;12.
- 498 6. Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). *Biosci Trends*
499 2020;14:69-71.
- 500 7. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology,
501 Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review.
502 *Jama* 2020;324:782-93.
- 503 8. de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights
504 into emerging coronaviruses. *Nat Rev Microbiol* 2016;14:523-34.
- 505 9. Burki T. CEPI: preparing for the worst. *Lancet Infect Dis* 2017;17:265-6.
- 506 10. World Health Organization, Draft landscape of COVID-19 candidate vaccines. 2020. at
507 [https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.](https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines))
- 508 11. Thanh Le T, Andreadakis Z, Kumar A, et al. The COVID-19 vaccine development
509 landscape. *Nat Rev Drug Discov* 2020;19:305-6.
- 510 12. Ahn DG, Shin HJ, Kim MH, et al. Current Status of Epidemiology, Diagnosis,
511 Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19). *J Microbiol*
512 *Biotechnol* 2020;30:313-24.
- 513 13. Roper RL, Rehm KE. SARS vaccines: where are we? *Expert Rev Vaccines* 2009;8:887-
514 98.
- 515 14. Hellerstein M. What are the roles of antibodies versus a durable, high quality T-cell
516 response in protective immunity against SARS-CoV-2? *Vaccine X* 2020;6:100076.
- 517 15. Dagotto G, Yu J, Barouch DH. Approaches and Challenges in SARS-CoV-2 Vaccine
518 Development. *Cell Host Microbe* 2020;28:364-70.
- 519 16. Enjuanes L, Zuñiga S, Castaño-Rodríguez C, Gutierrez-Alvarez J, Canton J, Sola I.
520 Molecular Basis of Coronavirus Virulence and Vaccine Development. *Adv Virus Res*
521 2016;96:245-86.
- 522 17. Sariol A, Perlman S. Lessons for COVID-19 Immunity from Other Coronavirus
523 Infections. *Immunity* 2020;53:248-63.
- 524 18. Du L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S. The spike protein of SARS-CoV--a target
525 for vaccine and therapeutic development. *Nat Rev Microbiol* 2009;7:226-36.
- 526 19. Ou X, Liu Y, Lei X, et al. Characterization of spike glycoprotein of SARS-CoV-2 on
527 virus entry and its immune cross-reactivity with SARS-CoV. *Nat Commun* 2020;11:1620.
- 528 20. Huang AT, Garcia-Carreras B, Hitchings MDT, et al. A systematic review of antibody
529 mediated immunity to coronaviruses: kinetics, correlates of protection, and association with
530 severity. *Nat Commun* 2020;11:4704.
- 531 21. Casadevall A, Joyner MJ, Pirofski LA. SARS-CoV-2 viral load and antibody responses:
532 the case for convalescent plasma therapy. *J Clin Invest* 2020;130:5112-4.

- 533 22. Tang F, Quan Y, Xin ZT, et al. Lack of peripheral memory B cell responses in recovered
534 patients with severe acute respiratory syndrome: a six-year follow-up study. *J Immunol*
535 2011;186:7264-8.
- 536 23. Kaneko N, Kuo HH, Boucau J, et al. Loss of Bcl-6-Expressing T Follicular Helper Cells
537 and Germinal Centers in COVID-19. *Cell* 2020;183:143-57.e13.
- 538 24. Chen Z, John Wherry E. T cell responses in patients with COVID-19. *Nat Rev Immunol*
539 2020;20:529-36.
- 540 25. Toor SM, Saleh R, Sasidharan Nair V, Taha RZ, Elkord E. T cell responses and therapies
541 against SARS-CoV-2 infection. *Immunology* 2020.
- 542 26. Ng OW, Chia A, Tan AT, et al. Memory T cell responses targeting the SARS coronavirus
543 persist up to 11 years post-infection. *Vaccine* 2016;34:2008-14.
- 544 27. Channappanavar R, Fett C, Zhao J, Meyerholz DK, Perlman S. Virus-specific memory
545 CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome
546 coronavirus infection. *J Virol* 2014;88:11034-44.
- 547 28. Pillet S, Couillard J, Trépanier S, et al. Immunogenicity and safety of a quadrivalent
548 plant-derived virus like particle influenza vaccine candidate-Two randomized Phase II clinical
549 trials in 18 to 49 and ≥ 50 years old adults. *PLoS One* 2019;14:e0216533.
- 550 29. Makarkov AI, Golizeh M, Ruiz-Lancheros E, et al. Plant-derived virus-like particle
551 vaccines drive cross-presentation of influenza A hemagglutinin peptides by human monocyte-
552 derived macrophages. *NPJ Vaccines* 2019;4:17.
- 553 30. Landry N, Pillet S, Favre D, et al. Influenza virus-like particle vaccines made in
554 *Nicotiana benthamiana* elicit durable, poly-functional and cross-reactive T cell responses to
555 influenza HA antigens. *Clin Immunol* 2014;154:164-77.
- 556 31. Ward BJ, Makarkov A, Séguin A, et al. Efficacy, immunogenicity, and safety of a plant-
557 derived, quadrivalent, virus-like particle influenza vaccine in adults (18-64 years) and older
558 adults (≥ 65 years): two multicentre, randomised phase 3 trials. *The Lancet* 2020.
- 559 32. D'Aoust MA, Couture MM, Charland N, et al. The production of hemagglutinin-based
560 virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza. *Plant*
561 *Biotechnol J* 2010;8:607-19.
- 562 33. Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T Cell Responses to SARS-CoV-2
563 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. *Cell*
564 2020;181:1489-501.e15.
- 565 34. Pillet S, Aubin É, Trépanier S, et al. Humoral and cell-mediated immune responses to
566 H5N1 plant-made virus-like particle vaccine are differentially impacted by alum and GLA-SE
567 adjuvants in a Phase 2 clinical trial. *npj Vaccines* 2018;3:3.
- 568 35. Cohet C, van der Most R, Bauchau V, et al. Safety of AS03-adjuvanted influenza
569 vaccines: A review of the evidence. *Vaccine* 2019;37:3006-21.
- 570 36. Hyer R, McGuire DK, Xing B, Jackson S, Janssen R. Safety of a two-dose investigational
571 hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant in adults. *Vaccine*
572 2018;36:2604-11.
- 573 37. Scheiermann J, Klinman DM. Clinical evaluation of CpG oligonucleotides as adjuvants
574 for vaccines targeting infectious diseases and cancer. *Vaccine* 2014;32:6377-89.
- 575 38. HEPLISAV-B®. [package insert]. Emeryville, CA: Dynavax Technologies Corporation;
576 2018.
- 577 39. Huang X, Yang Y. Targeting the TLR9-MyD88 pathway in the regulation of adaptive
578 immune responses. *Expert Opin Ther Targets* 2010;14:787-96.
- 579 40. Givord C, Welsby I, Detienne S, et al. Activation of the endoplasmic reticulum stress
580 sensor IRE1 α by the vaccine adjuvant AS03 contributes to its immunostimulatory properties. *npj*
581 *Vaccines* 2018;3:20.
- 582 41. van der Most RG, Clément F, Willekens J, et al. Long-Term Persistence of Cell-Mediated
583 and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03

- 584 Adjuvant System in Adults during Two Randomized Controlled Trials. *Clin Vaccine Immunol*
585 2017;24.
- 586 42. Pandemirix®. [package insert]. North Carolina. US. GlaxoSmith Kline.
- 587 43. Leroux-Roels G, Marchant A, Levy J, et al. Impact of adjuvants on CD4(+) T cell and B
588 cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial.
589 *Clin Immunol* 2016;169:16-27.
- 590 44. Penn-Nicholson A, Geldenhuys H, Burny W, et al. Safety and immunogenicity of
591 candidate vaccine M72/AS01E in adolescents in a TB endemic setting. *Vaccine* 2015;33:4025-
592 34.
- 593 45. Muralidharan A, Li C, Wang L, Li X. Immunopathogenesis associated with
594 formaldehyde-inactivated RSV vaccine in preclinical and clinical studies. *Expert Rev Vaccines*
595 2017;16:351-60.
- 596 46. Lambert PH, Ambrosino DM, Andersen SR, et al. Consensus summary report for
597 CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-
598 19 vaccines. *Vaccine* 2020;38:4783-91.
- 599 47. Crotty S. Follicular helper CD4 T cells (TFH). *Annu Rev Immunol* 2011;29:621-63.
- 600 48. Zhu J. T helper 2 (Th2) cell differentiation, type 2 innate lymphoid cell (ILC2)
601 development and regulation of interleukin-4 (IL-4) and IL-13 production. *Cytokine* 2015;75:14-
602 24.
- 603 49. Ward BJ, Landry N, Trépanier S, et al. Human antibody response to N-glycans present
604 on plant-made influenza virus-like particle (VLP) vaccines. *Vaccine* 2014;32:6098-106.
- 605 50. Pillet S, Aubin É, Trépanier S, et al. A plant-derived quadrivalent virus like particle
606 influenza vaccine induces cross-reactive antibody and T cell response in healthy adults. *Clin*
607 *Immunol* 2016;168:72-87.
- 608
- 609

610 **Appendix**

611 ***Author Contributions***

612 All authors contributed significantly to the research work. All company authors had full
613 access to the Tables and Figure data. BJW and NL made the final decision to submit the
614 manuscript.

615

616

617 **Acknowledgements**

618 The authors would like to acknowledge F. Roman, P. Boutet, Robbert Van Der Most, M.
619 Ceregido Perez, M. Koutsoukos and G. Preyon from GSK as well as R. Spencer, R. Janssen, D.
620 Campbell and D. Novack from Dynavax for critical review of the manuscript. The authors also
621 wish to acknowledge all the Medicago employees, their contractors and all of the volunteers
622 who participated in the study as well as the site investigators and their staff who conducted the
623 studies with a high degree of professionalism.

624

625 **Funding Statement**

626 The study was sponsored by Medicago Inc.

627

628

629

630

TABLES

631

632 Table 1: Summary of demographics and baseline characteristics (NCT04450004)

	CoVLP 3.75 µg			CoVLP 7.5 µg			CoVLP 15 µg			All
	Unadjuvanted	Adjuvanted with CpG 1018	Adjuvanted with AS03	Unadjuvanted	Adjuvanted with CpG 1018	Adjuvanted with AS03	Unadjuvanted	Adjuvanted with CpG 1018	Adjuvanted with AS03	
Subjects	20	20	20	20	20	20	20	20	20	180
Sex, n (%)										
Male	9 (45.0)	10 (50.0)	5 (25.0)	10 (50.0)	8 (40.0)	8 (40.0)	7 (35.0)	10 (50.0)	11 (55.0)	78 (43.3)
Female	11 (55.0)	10 (50.0)	15 (75.0)	10 (50.0)	12 (60.0)	12 (60.0)	13 (65.0)	10 (50.0)	9 (45.0)	102 (56.7)
Race, n (%)										
White	18 (90.0)	20 (100.0)	20 (100.0)	20 (100.0)	18 (90.0)	19 (95.0)	20 (100.0)	18 (90.0)	19 (95.0)	172 (95.6)
Black or African American	1 (5.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (5.0)	0 (0.0)	0 (0.0)	1 (5.0)	1 (5.0)	4 (2.2)
Asian	1 (5.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (5.0)	1 (5.0)	0 (0.0)	1 (5.0)	0 (0.0)	4 (2.2)
Ethnicity, n (%)										
Hispanic/Latinx	0 (0.0)	2 (10.0)	0 (0.0)	1 (5.0)	3 (15.0)	1 (5.0)	0 (0.0)	1 (5.0)	0 (0.0)	9 (5.0)
Age at Vaccination										
Mean ± SD	34.9 ± 8.3	35.3 ± 11.0	34.7 ± 9.1	35.6 ± 8.0	32.4 ± 9.5	37.2 ± 7.8	34.1 ± 9.6	32.0 ± 9.0	32.7 ± 9.1	34.3 ± 9.0
Median (range)	35 (18-49)	36 (18-53)	36 (19-49)	36 (20-50)	31 (19-52)	37 (21-55)	31.5 (22-54)	30 (19-51)	32.5 (18-52)	34 (18-55)

SD: Standard Deviation

633

634

635

636

637 **Table 2: Subject Disposition**


	CoVLP 3.75 µg			CoVLP 7.5 µg			CoVLP 15 µg			All
	Unadjuvanted n (%)	Adjuvanted with CpG 1018 n (%)	Adjuvanted with AS03 n (%)	Unadjuvanted n (%)	Adjuvanted with CpG 1018 n (%)	Adjuvanted with AS03 n (%)	Unadjuvanted n (%)	Adjuvanted with CpG 1018 n (%)	Adjuvanted with AS03 n (%)	
Screened Subjects										413
Screened Failure										233
Randomized Subjects	20	20	20	20	20	20	20	20	20	180
Vaccinated at Day 0	20 (100.0)	20 (100.0)	20 (100.0)	20 (100.0)	20 (100.0)	20 (100.0)	20 (100.0)	20 (100.0)	20 (100.0)	180 (100.0)
Vaccinated at Day 21	20 (100.0)	20 (100.0)	19 (95.0)	20 (100.0)	20 (100.0)	20 (100.0)	20 (100.0)	19 (95.0)	20 (100.0)	178 (98.9)
Safety Analysis Set	20 (100.0)	20 (100.0)	20 (100.0)	20 (100.0)	20 (100.0)	20 (100.0)	20 (100.0)	20 (100.0)	20 (100.0)	180 (100.0)
Per Protocol Set										
Day 21	20 (100.0)	20 (100.0)	20 (100.0)	20 (100.0)	20 (100.0)	20 (100.0)	20 (100.0)	19 (95.0)	20 (100.0)	179 (99.4)
Day 42	20 (100.0)	20 (100.0)	20 (100.0)	20 (100.0)	19 (95.0)	20 (100.0)	20 (100.0)	19 (95.0)	20 (100.0)	178 (98.9)
Completed Through Day 21	20 (100.0)	20 (100.0)	20 (100.0)	20 (100.0)	20 (100.0)	20 (100.0)	20 (100.0)	19 (95.0)	20 (100.0)	179 (99.4)
Early Withdrawal from Study	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (5.0)	0 (0.0)	1 (0.6)
Adverse Event	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Death	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

Lost to Follow-up	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Physician Decision	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Pregnancy Protocol Deviation	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Site	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Terminated by sponsor	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Study	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Termination by Sponsor	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (5.0)	0 (0.0)	1 (0.6)
Withdrawal by Subject	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Other	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

638

FIGURES

A. Solicited Local Reactions



B. Solicited Systemic Reactions






Figure 1 Solicited Local and Systemic AEs 7-Days After the First or Second Vaccine Dose.

Subjects were monitored for solicited local (panel A) and systemic (panel B) AEs from the time of vaccination through 7 days after vaccine administration. There was no grade 4 (life-threatening) events. Participants who reported 0 events make up the remainder of the 100% calculation (not shown). If any of the solicited AEs persisted beyond Day 7 after each vaccination (when applicable), it was recorded as unsolicited AEs.

A. SARS-CoV-2 Anti-Spike IgG



B. Pseudovirus Neutralizing Antibody Titers



C. Live Virus Neutralizing Antibody Titers





Figure 2 CoVLP Humoral Response.

Serum antibodies of subjects vaccinated with 3.75, 7.5, or 15 μ g CoVLP with or without AS03 or CpG1018 adjuvant, were measured to spike protein by ELISA (panel A) or by neutralization of pseudovirus (panel B), or live virus (panel C). Convalescent sera from recovered COVID-19 infected mildly, moderately, or severely ill patients were analyzed by anti-spike ELISA (n=35), and sera from mildly or moderately ill patients and one severely ill patient were analyzed by pseudovirion neutralization assay (n=21); results are shown in the right panels. All results are presented as reciprocal mid-point titers. Bars indicate geometric means. Error bars indicate 95% confidence intervals. Significant differences between days 0 and 21, or 0 and 42, for each vaccine regimen are indicated by # (#p<0.05, ##p<0.01, ###p<0.001, ####p<0.0001; unpaired T-test of log-transformed values, GraphPad Prism, v8.1.1). Significant differences between unadjuvanted and adjuvanted regimens for days 21 and 42 are indicated by * (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001; 2-way ANOVA of log-transformed values, GraphPad Prism, v8.1.1).

A. Vaccination One (Day 21)



B. Vaccination Two (Day 42)





Figure 3 Correlation Between Assays Quantifying Neutralizing Antibody Titers

Neutralizing serum antibodies of subjects vaccinated with 3.75, 7.5, or 15 μ g CoVLP with or without AS03 or CpG1018 adjuvant, were measured by neutralization of pseudovirion (x-axis) or live virus (y-axis)

twenty-one days after the first vaccination (panel A) or twenty-one days after the second vaccination (panel B). Results are presented as reciprocal titers. R are Pearson correlation coefficients (GraphPad Prism, v8.1.1).

A. IFN γ Cellular Immune Response



B. IL4 Cellular Immune Response




Figure 4 IFN- γ and IL-4 secreting cells as measured by ELISpot at Day 0, 21, and 42

Frequencies of antigen-specific T-cells producing interferon-gamma (Panel A) and interleukin-4 (Panel B) cellular immune responses at baseline (day 0) and 21 days after one immunization (day 21) or two immunizations (day 42) with 3.75, 7.5 or 15 μ g doses of CoVLP with or without adjuvants (CpG1018 and AS03) after restimulation ex vivo with recombinant spike peptide pool. Bars indicate medians and error bars indicate 95% CI. Significant differences between days 0 and 21 or between day 0 and 42 for each vaccine regimen are indicated by # (#P<0.05, ##P<0.01, ###P<0.001, ####P<0.0001; Unpaired T-test. Comparisons for each test to day 0 data are to the same pre-vaccination data set that include all subjects. The figure illustrates matched subject data. GraphPad Prism, v8.1.1). Significant difference between adjuvanted vaccine and unadjuvanted vaccine regiments at day 21 and 42 are indicated by * (*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001; Kruskal-Wallis, GraphPad Prism, v8.1.1).

Supplementary Appendix to

**Phase 1 trial of a Candidate Recombinant Virus-Like Particle Vaccine for Covid-19 Disease
Produced in Plants**

Supplementary Methods:

Vaccination Stopping Rules

Safety monitoring of safety signals were and will be performed throughout the study. Stopping rules or conditions for stopping this clinical trial would occur if there was clear evidence of harm or harmful effects such as SAEs related to the treatment (study vaccine). A SAE which was thought to be unrelated to the study vaccine would not warrant stopping the trial.

The following event(s) may result in a halt to the study, for further review and assessment of the event(s):

- Any death occurring during the study;
- Any vaccine-related SAE during the study;
- Any life-threatening (Grade 4) vaccine-related AE during the study;
- If 10 % or more of subjects in a single treatment group, experience the same or similar listed event(s) that cannot be clearly attributed to another cause:
 - a severe (Grade 3 or higher) vaccine-related AE during the study;
 - a severe (Grade 3 or higher) vaccine-related vital sign(s) abnormality;
 - a severe (Grade 3 or higher) vaccine-related clinical laboratory abnormality.

In the case that a pre-defined safety signal is met in any treatment group, subsequent dosing will result in at least a transient halt in the study to permit a complete evaluation of the reported event(s) and to consult an IDMC. A decision as to whether the study can progress as planned must be made and documented in the event of any safety signal. If a stopping rule has been met once all subjects have been vaccinated in the study, the IDMC will be notified by a Note To File (NTF) for their information purposes.

Immunological Assay Method Details

Evaluation of SARS-CoV-2 Humoral Response

SARS-CoV-2 Spike Protein ELISA

Briefly, SARS-Cov2 Spike protein (SARS-Cov2/Wuhan/2019, Immune Technology Corp.) was coated onto a flat-bottom 96-well microplate at a concentration of 1 μ g/mL in sodium carbonate 50mM (overnight; 4°C). Following washing steps (PBS-Tween), plates were blocked using Blotto 5% (Rockland Inc.) in PBS (1-2 hours; 37°C). Following washing steps, serially diluted sera (starting dilution 1/100, 4-fold dilutions, 8 dilutions, in PBS-Tween-Blotto) were added to the wells, in duplicates, and incubated at 37°C for 1 hour. Plates were washed and incubated with secondary antibody (anti-Human IgG (H+L) antibody, Peroxidase-labeled, Seracare), diluted at 1/20 000 in PBS-Tween-Blotto and incubated at 37°C for 1 hour. Plates were washed and incubated with peroxidase substrate (SureBlue TMB, Seracare) for 20 minutes at room temperature. Reaction was stopped using hydrochloric acid and absorbance was read at 450nm, within 2 hours (Variaskan Flash microplate reader, Thermo Scientific). Optical density (OD) results for the serial dilutions were used to generate a 4-parameter logistic regression (4PL). The titer was defined as the reciprocal dilution of the sample for which the OD is equal to a fixed cut-point value. Samples below cut-point were attributed a value of 50 (half the minimum required dilution).

SARS-CoV-2 Pseudovirus Neutralisation Assay (PNA)

Neutralizing antibody analysis was performed using a cell-based pseudotyped virus neutralisation assay (Nexelis, Quebec, Canada). Pseudotyped virus particles were first generated using a genetically modified Vesicular Stomatitis Virus backbone from which the glycoprotein G was removed and luciferase reporter introduced (rVSV Δ G-luciferase, Kerafast) to allow quantification using relative luminescence units (RLU). This rVSV Δ G-Luc virus was transduced into HEK293T cells that had previously been transduced with SARS-Cov-2 Spike glycoprotein (NXL137-1 in POG2 containing 2019-nCOV Wuhan-Hu-1; Genbank: MN908947) from which the last nineteen amino acids of the cytoplasmic tail were removed (rVSV Δ G-Luc-Spike Δ CT).

Serial dilutions (starting dilution of 1/10; 2-fold; 8 dilutions, in complete growth media) of the heat-inactivated human sera (56°C; 30min) were prepared in a 96-well plate, in duplicates. The SARS-Cov-2 pseudovirus (in complete growth media) was added to the sera dilutions to reach a target concentration equivalent to approximately 150,000 RLU/well and mixture was incubated at 37°C with 5% CO₂ supplementation for 1 hour. Serum-pseudovirus complexes were then transferred onto plates previously seeded overnight with Vero E6 cells (ATCC CRL-1586), expressing ACE-2 receptor, and incubated at

37°C with 5% CO₂ supplementation for 20-24 hours. Once incubation was completed, cells were lysed and samples equilibrated using ONE-Glo EX luciferase assay system (Promega), incubated for 3 minutes at room temperature, and luminescence level read using a luminescence plate reader (i3x plate reader, Molecular Devices). The resulting RLU was inversely proportional to the level of neutralizing antibodies present in the serum. For each sample, the neutralizing titer was established as the reciprocal dilution corresponding to the 50% neutralization (NT50), when compared to the pseudoparticle control. The NT50 was interpolated from a linear regression using the two dilutions flanking the 50% neutralisation. Samples below cut-off were attributed a value of 5 (half the minimum required dilution).

SARS-CoV-2 Microneutralization CPE-based assay

Neutralizing antibody analysis was also performed using a cell-based cytopathic effect (CPE) assay (VisMederi, Sienna, Italy). Sera sample were first heat inactivated (56°C; 30min) and then serially diluted (starting dilution of 1/10, 2-fold; 8 dilutions, in complete growth media). Wild-type SARS-Co-2 virus (2019 nCOV ITALY/INMI1, provided by EVAg; Genbank: MT066156) was then added at final concentration of 25 TCID₅₀/mL (in complete growth media), and plates were incubated for 1 hour at 37°C with 5% CO₂ supplementation. At the end of the incubation, the mixture was transferred onto duplicate 96-well microtiter plates pre-seeded overnight with Vero E6 cells (ATCC CRL-1586), expressing ACE-2 receptor. Plates were then incubated for 3 days at 37°C with 5% CO₂ supplementation. Cytopathic effect (CPE) was then quantified using an inverted optical microscope. The microneutralization titer (MNt) was defined as the reciprocal of the highest sample dilution that protects from CPE at least 50% of the cells. If no neutralization was observed, samples were attributed a titer value of 5 (half the minimum required dilution).

Evaluation of SARS-CoV-2 Cell-Mediated Immune Response

Interferon-γ ELISpot

Cell-mediated immune response was evaluated using an Interferon-γ ELISpot assay (Human IFN-γ ELISpot assay, Cellular Technology Limited (CTL), USA). Cryopreserved peripheral blood mononuclear cells (PBMC) were rapidly thawed and allowed to rest between 2 to 3 hours at 37°C with 5% CO₂ supplementation, in CTL-Test media supplemented with 1% Glutamine and 1% Penicillin/Streptomycin. Cells were enumerated and dispensed at 0.5x10⁶ cells per well, in duplicates, onto PVDF filter plates pre-coated with an IFN-γ specific capture antibody. Cells were stimulated using a pool of peptides (15-mer peptides) overlapping the full sequence of SARS-Cov-2 spike protein (USA-CA2/2020, Genbank: MN994468.1) at a concentration of 2.19 µg/mL, for 18-24 hours, at 37°C with 5% CO₂ supplementation.

After washes (PBS-Tween), biotinylated anti-interferon- γ detection antibody was added to the plates and incubated for 2 hours at room temperature after which, following another round of washes, a streptavidin-alkaline phosphatase conjugate was added and incubated for 30 minutes at room temperature. After washing steps, substrate solution was added, incubated at room temperature for 15 minutes, after which plate was rinsed and left to air-dry pending spot enumeration, using an ELISpot reader (ImmunoSpot S6 Universal Analyzer, Cellular Technology Limited). Mean of peptide pool stimulation duplicates was calculated and normalized using the mean of the negative control replicates (control media) and multiplied by a factor of 2 to express cells counts per million cells.

Interleukin-4 (IL-4) ELISpot

Cell-mediated immune response was evaluated using an IL-4 ELISpot assay (Human IL-4 ELISpot assay, Cellular Technology Limited (CTL), Cleveland, OH, USA). Cryopreserved peripheral blood mononuclear cells (PBMC) were rapidly thawed and allowed to rest between 2 to 3 hours at 37°C with 5% CO₂ supplementation, in CTL-Test media supplemented with 1% Glutamine and 1% Penicillin/Streptomycin. Cells were enumerated and dispensed at 0.5x10⁶ cells per well, in duplicates, onto PVDF filter plates pre-coated with an IL-4 specific capture antibody. Cells were stimulated using a pool of peptides (15-mer peptides) overlapping the full sequence of SARS-Cov-2 spike protein (USA-CA2/2020, Genbank: MN994468.1) at a concentration of 2.19 μ g/mL, for 32-48 hours, at 37°C with 5% CO₂ supplementation. After washes (PBS-Tween), biotinylated anti-IL-4 detection antibody was added to the plates and incubated for 2 hours at room temperature after which, following another round of washes, a streptavidin-alkaline phosphatase conjugate was added and incubated for 30 minutes at room temperature. After washing steps, substrate solution was added, incubated at room temperature for 15 minutes, after which plate was rinsed and left to air-dry pending spot enumeration, using an ELISpot reader (ImmunoSpot S6 Universal Analyzer, Cellular Technology Limited). Mean of peptide pool stimulation duplicates was calculated and normalized using the mean of the negative control replicates (control media) and multiplied by a factor of 2 to express cells counts per million cells.

Convalescent sera description

Sera from Covid-19 convalescent patients were collected from a total of 34 individuals with confirmed disease diagnosis. Time between the onset of the symptoms and sample collection varied between 27 and 105 days. Three samples were collected by Solomon Park (Burien, WA, USA), 20 by Sanguine BioSciences (Sherman Oaks, CA, USA) and 11 from McGill University Health Centre. Disease severity were ranked as mild (Covid-19 symptoms without shortness of breath), moderate (shortness of breath reported), and severe (hospitalized). These samples were analysed in parallel of clinical study samples, using the same assay as described above. Samples from severely ill were analyzed by serum IgG ELISA only. Demographic characteristics are provided in Supplementary Table 1.

Supplementary Table 1 Summary of Covid-19 Patients Providing Convalescent Sera

Characteristics	Mild	Moderate	Severe
Subjects	16	8	11
Sex, n (%)			
Male	10 (62.5%)	2 (25.0%)	8 (72.7%)
Female	5 (31.3%)	6 (75.0%)	3 (27.3%)
Race, n (%)			
White	7 (43.8%)	6 (75.04%)	5 (45.5%)
Black or African American	1 (6.3%)	0 (0.0%)	5 (45.5%)
Asian	4 (25.0%)	2 (25.0%)	0 (0.0%)
Ethnicity, n (%)			
Hispanic/Latinx	2 (12.5%)	1 (12.5%)	1 (9.1%)
Age:			
Mean \pm SD	42.7 \pm 13.6	37.8 \pm 13.0	51.9 \pm 16.0
Median (range)	39 (20-66)	40.5 (19-58)	50.0 (28-82)

SD: Standard Deviation

Adverse Event Severity Evaluation and the Monitoring of Adverse Events of Special Interest

Adverse Event of Special Interest (AESI)

AESI for CoVLP Vaccine – Vaccine Enhanced Disease (VED)

Safety signal of VED after exposure to the Coronavirus-Like Particle COVID-19 Vaccine was closely monitored and assessed by retrieving data for this AESI as follows: AEs within the system organ class (SOC): immune system disorders and high level group term (HLGT): lower respiratory tract disorders (excluding obstruction and infection), cardiac disorders, signs and symptoms not elsewhere classified (NEC), vascular disorders, heart failures NEC, arteriosclerosis, stenosis, vascular insufficiency and necrosis, cardiac arrhythmias, myocardial disorders, and vascular hemorrhagic disorders. High level term (HLT): renal failure and impairment and preferred term (PT): pericarditis, coagulopathy, deep vein thrombosis, pulmonary embolism, cerebrovascular accidents, peripheral ischemia, liver injury, Guillain-Barre syndrome, anosmia, ageusia, encephalitis, chilblains, vasculitis, erythema multiforme (based on standardized MedDRA® classification)^{1,2} that require inpatient hospitalization (≥ 24 hours) and have laboratory confirmed SARS-Cov-2 infection will be monitored for assessment of any potential case of VED.

AESI for CoVLP Vaccine – Hypersensitivity Reactions

All reported events were also monitored for hypersensitivity reactions after exposure to the Coronavirus-Like Particle COVID-19 Vaccine. In eight clinical studies conducted to date with the Quadrivalent VLP Influenza Vaccine (QVLP) produced using similar plant-based technology, all reported events were monitored for a possible hypersensitivity component (events were searched using both narrow and broad standardized MedDRA® queries). Based on these data, there was a single case of possible early anaphylactic reaction associated with use of QVLP in humans. A small number of subjects had potential hypersensitivity reactions judged to be related to vaccine administration (no more than 0.3 % of subjects in any given QVLP treatment group experienced one of these events) and the events were distributed fairly evenly among treatment groups, including the placebo and the active comparator groups. However, since severe reactions are considered to be an important potential risk (based on the theoretical risk that using plants for the production of biotherapeutics may induce hypersensitivity), Medicago required that appropriate medical treatment and supervision were available to manage any possible anaphylactic reactions in this study. To collect data on these events, Medicago closely monitored and assessed allergic reactions assessed by the site Investigators as related to the Investigational product as AESIs.

AESI for Adjuvant – Potential Immune-Mediated Diseases (pIMD)

Potential immune-mediated diseases are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.

Supplementary Table 2 List of Potential Immune-Mediated Diseases

Neuroinflammatory disorders	Musculoskeletal disorders	Skin disorders
<ul style="list-style-type: none"> • Cranial nerve neuropathy, including paralysis and paresis (eg, Bell’s palsy). • Optic neuritis. • Multiple sclerosis. • Transverse myelitis. • Guillain-Barré syndrome, including Miller Fisher syndrome and other variants. • Acute disseminated encephalomyelitis, including site specific variants, eg, noninfectious encephalitis, encephalomyelitis, myelitis, myeloradiculoneuritis. • Myasthenia gravis, including Lambert-Eaton myasthenic syndrome. • Demyelinating peripheral neuropathies and plexopathies including: <ul style="list-style-type: none"> - Chronic inflammatory demyelinating polyneuropathy. - Multifocal motor neuropathy. - Polyneuropathies associated with monoclonal gammopathy. • Narcolepsy. • Tolosa Hunt syndrome. 	<ul style="list-style-type: none"> • Systemic lupus erythematosus and associated conditions. • Systemic scleroderma (systemic sclerosis), including: <ul style="list-style-type: none"> - Diffuse scleroderma. - CREST syndrome. • Idiopathic inflammatory myopathies, including: <ul style="list-style-type: none"> - Dermatomyositis. - Polymyositis. • Anti-synthetase syndrome. • Rheumatoid arthritis and associated conditions including: <ul style="list-style-type: none"> - Juvenile idiopathic arthritis. - Still’s disease. • Polymyalgia rheumatica. • Spondyloarthropathies, including: <ul style="list-style-type: none"> - Ankylosing spondylitis. - Reactive arthritis (Reiter’s syndrome). - Undifferentiated spondyloarthritis. - Psoriatic arthritis. - Enteropathic arthritis. • Relapsing polychondritis. • Mixed connective tissue disorder. • Gout. 	<ul style="list-style-type: none"> • Psoriasis. • Vitiligo. • Erythema nodosum. • Autoimmune bullous skin diseases (including pemphigus, pemphigoid, and dermatitis herpetiformis). • Lichen planus. • Sweet’s syndrome. • Localized scleroderma (morphea). • Cutaneous lupus erythematosus. • Rosacea.
Vasculitis	Blood disorders	Others
<ul style="list-style-type: none"> • Large vessels vasculitis including: <ul style="list-style-type: none"> - Giant cell arteritis (temporal arteritis). - Takayasu’s arteritis. • Medium sized and/or small vessels vasculitis including: <ul style="list-style-type: none"> - Polyarteritis nodosa. - Kawasaki’s disease. - Microscopic polyangiitis. - Wegener’s granulomatosis (granulomatosis with polyangiitis). 	<ul style="list-style-type: none"> • Autoimmune hemolytic anemia. • Autoimmune thrombocytopenia. • Antiphospholipid syndrome. • Pernicious anemia. • Autoimmune aplastic anemia. • Autoimmune neutropenia. • Autoimmune pancytopenia. 	<ul style="list-style-type: none"> • Autoimmune glomerulonephritis including: <ul style="list-style-type: none"> - IgA nephropathy. - Glomerulonephritis rapidly progressive. - Membranous glomerulonephritis. - Membranoproliferative glomerulonephritis. - Mesangioproliferative glomerulonephritis. - Tubulointerstitial nephritis and uveitis syndrome.

Vasculitis (continued)	Blood disorders (continued)	Others (continued)
<ul style="list-style-type: none"> - Churg–Strauss syndrome (allergic granulomatous angiitis or eosinophilic granulomatosis with polyangiitis). - Buerger’s disease (thromboangiitis obliterans). - Necrotizing vasculitis (cutaneous or systemic). - Antineutrophil cytoplasmic antibody (ANCA) positive vasculitis (type unspecified). - Henoch-Schonlein purpura (IgA vasculitis). - Behcet’s syndrome. - Leukocytoclastic vasculitis. 		<ul style="list-style-type: none"> • Ocular autoimmune diseases including: <ul style="list-style-type: none"> - Autoimmune uveitis. - Autoimmune retinitis. • Autoimmune myocarditis/cardiomyopathy. • Sarcoidosis. • Stevens-Johnson syndrome. • Sjögren’s syndrome. • Alopecia areata. • Idiopathic pulmonary fibrosis. • Goodpasture syndrome. • Raynaud’s phenomenon.
Liver disorders	Gastrointestinal disorders	Endocrine disorders
<ul style="list-style-type: none"> • Autoimmune hepatitis. • Primary biliary cirrhosis. • Primary sclerosing cholangitis. • Autoimmune cholangitis. 	<ul style="list-style-type: none"> • Inflammatory bowel disease, including: <ul style="list-style-type: none"> - Crohn’s disease. - Ulcerative colitis. - Microscopic colitis. - Ulcerative proctitis. • Celiac disease. • Autoimmune pancreatitis. 	<ul style="list-style-type: none"> • Autoimmune thyroiditis (including Hashimoto thyroiditis). • Grave’s or Basedow’s disease. • Diabetes mellitus type 1. • Addison’s disease. • Polyglandular autoimmune syndrome. • Autoimmune hypophysitis.

Severity of Grades for Solicited Local and Systemic Adverse Events

Supplementary Table 3 List of Potential Immune-Mediated Diseases

Symptoms	Severity				
	None	Grade 1 (Mild)	Grade 2 (Moderate)	Grade 3 (Severe)	Grade 4 (Potentially life-threatening)
Injection Site Adverse Events (Local Adverse Events)					
Erythema (redness)	< 25 mm	25 - 50 mm	51 - 100 mm	> 100 mm	Necrosis or exfoliative dermatitis
Swelling	< 25 mm	25 - 50 mm and does not interfere with activity	51 – 100 mm or interferes with activity	> 100 mm or prevents daily activity	Necrosis
Pain	None	Does not interfere with activity	Repeated use of non-narcotic pain reliever for more than 24 hours or interferes with activity	Any use of narcotic pain reliever or prevents daily activity	Results in a visit to emergency room (ER) or hospitalization
Solicited Systemic Adverse Events					
Fever (°C or °F)	< 38.0 °C < 100.4 °F	38.0 - 38.4 °C 100.4 - 101.1 °F	38.5 - 38.9 °C 101.2 - 102.0 °F	39.0 - 40.0 °C 102.1 - 104.0 °F	> 40.0 °C > 104.0 °F
Headache	None	No interference with activity	Repeated use of non-narcotic pain reliever for more than 24 hours or some interference with activity	Significant; any use of narcotic pain reliever or prevents daily activity	Results in a visit to emergency room (ER) or hospitalization
Fatigue	None	No interference with activity	Some interference with activity	Significant; prevents daily activity	Results in a visit to emergency room (ER) or hospitalization
Muscle aches	None	No interference with activity	Some interference with activity	Significant; prevents daily activity	Results in a visit to emergency room (ER) or hospitalization
Joint aches, chills, feeling of general discomfort or uneasiness (malaise), swelling in the axilla, swelling in the neck, swelling in the groin, swelling in the chest wall	None	No interference with activity	Some interference with activity not requiring medical intervention	Prevents daily activity and requires medical intervention	Results in a visit to emergency room (ER) or hospitalization

Source: FDA. Guidance for Industry: Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. 2007.

Solicited Adverse Events

Supplementary Table 4 Solicited Adverse Events by Severity Grades from Days 0 to 7 (Safety Analysis Set) – 3.75 µg

Symptoms	Severity	COVLP 3.75 ug unadjuvanted		COVLP 3.75 ug with CpG 1018		COVLP 3.75 ug with AS03	
		Vacc. 1 N=20	Vacc 2 N=20	Vacc. 1 N=20	Vacc 2 N=20	Vacc 1 N=20	Vacc 2 N=19
Redness at injection site	Grade 1	1 (5.0)	0 (0.0)	0 (0.0)	1 (5.0)	1 (5.0)	2 (10.5)
	Grade 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3 (15.8)
	Grade 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (5.3)
Swelling at injection site	Grade 1	0 (0.0)	1 (5.0)	1 (5.0)	3 (15.0)	3 (15.0)	5 (26.3)
	Grade 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Grade 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (5.3)
Pain at injection site	Grade 1	4 (20.0)	3 (15.0)	17 (85.0)	15 (75.0)	18 (90.0)	16 (84.2)
	Grade 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (5.0)	3 (15.8)
	Grade 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fever	Grade 1	0 (0.0)	0 (0.0)	1 (5.0)	0 (0.0)	0 (0.0)	5 (26.3)
	Grade 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (10.5)
	Grade 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Headache	Grade 1	3 (15.0)	2 (10.0)	9 (45.0)	6 (30.0)	6 (30.0)	6 (31.6)
	Grade 2	0 (0.0)	1 (5.0)	1 (5.0)	2 (10.0)	0 (0.0)	5 (26.3)
	Grade 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Muscle aches	Grade 1	0 (0.0)	0 (0.0)	1 (5.0)	2 (10.0)	1 (5.0)	4 (21.1)
	Grade 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3 (15.8)
	Grade 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Joint aches	Grade 1	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (5.0)	1 (5.3)
	Grade 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (5.3)
	Grade 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatigue	Grade 1	5 (25.0)	2 (10.0)	6 (30.0)	5 (25.0)	7 (35.0)	5 (26.3)
	Grade 2	0 (0.0)	0 (0.0)	1 (5.0)	0 (0.0)	0 (0.0)	5 (26.3)
	Grade 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (5.0)	1 (5.3)
Chills	Grade 1	1 (5.0)	1 (5.0)	1 (5.0)	0 (0.0)	0 (0.0)	8 (42.1)
	Grade 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	4 (21.1)
	Grade 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Discomfort or uneasiness	Grade 1	2 (10.0)	1 (5.0)	3 (15.0)	1 (5.0)	3 (15.0)	4 (21.1)
	Grade 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	5 (26.3)
	Grade 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (5.3)
Swelling in the neck	Grade 1	1 (5.0)	0 (0.0)	4 (20.0)	1 (5.0)	0 (0.0)	1 (5.3)
	Grade 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Grade 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Swelling in the axilla	Grade 1	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Grade 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Grade 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Swelling in the groin	Grade 1	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Grade 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Grade 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Swelling in the chest wall	Grade 1	0 (0.0)	0 (0.0)	1 (5.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Grade 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Grade 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

**Supplementary Table 5 Solicited Adverse Events by Severity Grades from Days 0 to 7 (Safety Analysis Set)
– 7.5 µg**

Symptoms	Severity	COVLP 7.5 ug unadjuvanted		COVLP 7.5 ug with CpG 1018		COVLP 7.5 ug with AS03	
		Vacc. 1 N=20	Vacc 2 N=20	Vacc. 1 N=20	Vacc 2 N=20	Vacc 1 N=20	Vacc 2 N=20
Redness at injection site	Grade 1	0 (0.0)	0 (0.0)	0 (0.0)	1 (5.0)	0 (0.0)	4 (20.0)
	Grade 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (5.0)
	Grade 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (10.0)
Swelling at injection site	Grade 1	0 (0.0)	1 (5.0)	4 (20.0)	3 (15.0)	6 (30.0)	5 (25.0)
	Grade 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3 (15.0)
	Grade 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Pain at injection site	Grade 1	6 (30.0)	2 (10.0)	15 (75.0)	12 (60.0)	15 (75.0)	14 (70.0)
	Grade 2	0 (0.0)	0 (0.0)	1 (5.0)	2 (10.0)	1 (5.0)	4 (20.0)
	Grade 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fever	Grade 1	0 (0.0)	0 (0.0)	0 (0.0)	1 (5.0)	0 (0.0)	3 (15.0)
	Grade 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (5.0)
	Grade 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Headache	Grade 1	6 (30.0)	2 (10.0)	8 (40.0)	2 (10.0)	2 (10.0)	9 (45.0)
	Grade 2	0 (0.0)	2 (10.0)	0 (0.0)	1 (5.0)	0 (0.0)	6 (30.0)
	Grade 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Muscle aches	Grade 1	1 (5.0)	1 (5.0)	1 (5.0)	2 (10.0)	0 (0.0)	8 (40.0)
	Grade 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (10.0)
	Grade 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Joint aches	Grade 1	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	5 (25.0)
	Grade 2	0 (0.0)	1 (5.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (10.0)
	Grade 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatigue	Grade 1	3 (15.0)	1 (5.0)	3 (15.0)	6 (30.0)	3 (15.0)	12 (60.0)
	Grade 2	0 (0.0)	0 (0.0)	1 (5.0)	0 (0.0)	1 (5.0)	3 (15.0)
	Grade 3	0 (0.0)	0 (0.0)	0 (0.0)	1 (5.0)	0 (0.0)	0 (0.0)
Chills	Grade 1	1 (5.0)	1 (5.0)	1 (5.0)	4 (20.0)	0 (0.0)	9 (45.0)
	Grade 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3 (15.0)
	Grade 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Discomfort or uneasiness	Grade 1	0 (0.0)	0 (0.0)	2 (10.0)	2 (10.0)	0 (0.0)	8 (40.0)
	Grade 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3 (15.0)
	Grade 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Swelling in the neck	Grade 1	1 (5.0)	0 (0.0)	0 (0.0)	1 (5.0)	1 (5.0)	2 (10.0)
	Grade 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Grade 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Swelling in the axilla	Grade 1	1 (5.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (5.0)
	Grade 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Grade 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Swelling in the groin	Grade 1	1 (5.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (5.0)
	Grade 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Grade 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Swelling in the chest wall	Grade 1	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (5.0)
	Grade 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Grade 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

Supplementary Table 6 Solicited Adverse Events by Severity Grades from Days 0 to 7 (Safety Analysis Set) – 15 µg

Symptoms	Severity	COVLP 15 ug unadjuvanted		COVLP 15 ug with CpG 1018		COVLP 15 ug with AS03	
		Vacc 1	Vacc 2	Vacc. 1	Vacc 2	Vacc 1	Vacc 2
		N=20	N=20	N=20	N=19	N=20	N=20
Redness at injection site	Grade 1	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (5.0)	3 (15.0)
	Grade 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (5.0)
	Grade 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Swelling at injection site	Grade 1	0 (0.0)	0 (0.0)	2 (10.0)	1 (5.3)	3 (15.0)	3 (15.0)
	Grade 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (5.0)	1 (5.0)
	Grade 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (5.0)
Pain at injection site	Grade 1	6 (30.0)	7 (35.0)	16 (80.0)	13 (68.4)	13 (65.0)	14 (70.0)
	Grade 2	0 (0.0)	1 (5.0)	0 (0.0)	1 (5.3)	4 (20.0)	2 (10.0)
	Grade 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fever	Grade 1	0 (0.0)	0 (0.0)	0 (0.0)	1 (5.3)	0 (0.0)	5 (25.0)
	Grade 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (5.0)
	Grade 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Headache	Grade 1	3 (15.0)	2 (10.0)	6 (30.0)	4 (21.1)	7 (35.0)	6 (30.0)
	Grade 2	1 (5.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (5.0)	3 (15.0)
	Grade 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Muscle aches	Grade 1	1 (5.0)	0 (0.0)	2 (10.0)	1 (5.3)	1 (5.0)	2 (10.0)
	Grade 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3 (15.0)
	Grade 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Joint aches	Grade 1	0 (0.0)	0 (0.0)	1 (5.0)	0 (0.0)	1 (5.0)	2 (10.0)
	Grade 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (5.0)
	Grade 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fatigue	Grade 1	0 (0.0)	1 (5.0)	0 (0.0)	6 (31.6)	4 (20.0)	9 (45.0)
	Grade 2	1 (5.0)	0 (0.0)	1 (5.0)	0 (0.0)	0 (0.0)	2 (10.0)
	Grade 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Chills	Grade 1	0 (0.0)	0 (0.0)	0 (0.0)	2 (10.5)	1 (5.0)	6 (30.0)
	Grade 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	(10.0)
	Grade 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Discomfort or uneasiness	Grade 1	0 (0.0)	0 (0.0)	1 (5.0)	2 (10.5)	2 (10.0)	4 (20.0)
	Grade 2	0 (0.0)	0 (0.0)	1 (5.0)	0 (0.0)	0 (0.0)	2 (10.0)
	Grade 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Swelling in the neck	Grade 1	2 (10.0)	0 (0.0)	1 (5.0)	1 (5.3)	2 (10.0)	3 (15.0)
	Grade 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Grade 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Swelling in the axilla	Grade 1	0 (0.0)	0 (0.0)	0 (0.0)	1 (5.3)	2 (10.0)	2 (10.0)
	Grade 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Grade 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Swelling in the groin	Grade 1	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Grade 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Grade 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Swelling in the chest wall	Grade 1	0 (0.0)	0 (0.0)	1 (5.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Grade 2	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Grade 3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

Supplementary Table 7 Treatment- Emergent Unsolicited Adverse Events up to 21 days after last vaccination (Safety Analysis Set) – Dose 3.75 µg

Adverse Event SOC/PT	COVLP 3.75 ug unadjuvanted (N=20)	COVLP 3.75 ug with CpG 1018 (N=20)	COVLP 3.75 ug with AS03 (N=20)
Subjects with at least one unsolicited AE	8	9	8
Eye disorders			
Conjunctivitis allergic	1 (5.0)	0 (0.0)	0 (0.0)
Gastrointestinal disorders			
Abdominal pain upper	0 (0.0)	1 (5.0)	0 (0.0)
General disorders and administration site conditions			
Chest discomfort	1 (5.0)	0 (0.0)	0 (0.0)
Fatigue	0 (0.0)	1 (5.0)	0 (0.0)
Feeling hot	0 (0.0)	0 (0.0)	1 (5.0)
Injection site pain	0 (0.0)	0 (0.0)	1 (5.0)
Injection site swelling	0 (0.0)	0 (0.0)	1 (5.0)
Infections and infestations			
Bacterial vaginosis	0 (0.0)	0 (0.0)	1 (5.0)
Hordeolum	0 (0.0)	1 (5.0)	0 (0.0)
Vaginal infection	0 (0.0)	0 (0.0)	1 (5.0)
Injury, poisoning and procedural complications			
Ligament sprain	1 (5.0)	0 (0.0)	0 (0.0)
Tooth fracture	1 (5.0)	0 (0.0)	0 (0.0)
Investigations			
Blood glucose increased	0 (0.0)	1 (5.0)	0 (0.0)
Musculoskeletal and connective tissue disorders			
Plantar fasciitis	0 (0.0)	1 (5.0)	0 (0.0)
Nervous system disorders			
Dizziness exertional	0 (0.0)	1 (5.0)	0 (0.0)
Paraesthesia	1 (5.0)	0 (0.0)	0 (0.0)
Psychiatric disorders			
Depressed mood	0 (0.0)	1 (5.0)	0 (0.0)
Irritability	0 (0.0)	1 (5.0)	0 (0.0)
Reproductive system and breast disorders			
Dysmenorrhoea	0 (0.0)	0 (0.0)	1 (5.0)
Respiratory, thoracic and mediastinal disorders			
Asthma exercise induced	0 (0.0)	0 (0.0)	1 (5.0)
Skin and subcutaneous tissue disorders			

Adverse Event SOC/PT	COVLP 3.75 ug unadjuvanted (N=20)	COVLP 3.75 ug with CpG 1018 (N=20)	COVLP 3.75 ug with AS03 (N=20)
Rash maculo-papular	1 (5.0)	0 (0.0)	0 (0.0)

Supplementary Table 8 Treatment- Emergent Unsolicited Adverse Events up to 21 days after last vaccination (Safety Analysis Set) – Dose 7.5 µg


Adverse Event SOC/PT	COVLP 7.5 ug unadjuvanted (N=20)	COVLP 7.5 ug with CpG 1018 (N=20)	COVLP 7.5 ug with AS03 (N=20)
Subjects with at least one unsolicited AE	9	11	7
Blood and lymphatic system disorders			
Lymphadenopathy	0 (0.0)	0 (0.0)	1 (5.0)
Gastrointestinal disorders			
Diarrhoea	0 (0.0)	0 (0.0)	1 (5.0)
General disorders and administration site conditions			
Injection site papule	0 (0.0)	0 (0.0)	1 (5.0)
Investigations			
Blood pressure decreased	1 (5.0)	0 (0.0)	0 (0.0)
Blood pressure increased	1 (5.0)	0 (0.0)	0 (0.0)
Metabolism and nutrition disorders			
Hypercholesterolaemia	1 (5.0)	0 (0.0)	0 (0.0)
Musculoskeletal and connective tissue disorders			
Costochondritis	0 (0.0)	1 (5.0)	0 (0.0)
Limb discomfort	0 (0.0)	1 (5.0)	0 (0.0)
Pain in extremity	0 (0.0)	0 (0.0)	1 (5.0)
Nervous system disorders			
Dizziness	0 (0.0)	1 (5.0)	0 (0.0)
Psychiatric disorders			
Anxiety	0 (0.0)	1 (5.0)	0 (0.0)
Reproductive system and breast disorders			
Vulvovaginal pruritus	0 (0.0)	1 (5.0)	0 (0.0)
Respiratory, thoracic and mediastinal disorders			
Dry throat	1 (5.0)	0 (0.0)	0 (0.0)
Rhinitis allergic	1 (5.0)	0 (0.0)	0 (0.0)
Throat irritation	0 (0.0)	2 (10.0)	0 (0.0)
Skin and subcutaneous tissue disorders			
Dermatitis contact	0 (0.0)	1 (5.0)	0 (0.0)
Erythema	0 (0.0)	1 (5.0)	0 (0.0)
Rash	1 (5.0)	0 (0.0)	0 (0.0)

Supplementary Table 9 Treatment- Emergent Unsolicited Adverse Events up to 21 days after last vaccination (Safety Analysis Set) – Dose 15 µg

Adverse Event SOC/PT	COVLP 15 ug unadjuvanted (N=20)	COVLP 15 ug with CpG 1018 (N=20)	COVLP 15 ug with AS03 (N=20)
Subjects with at least one unsolicited AE	8	6	11
Ear and labyrinth disorders			
Ear pain	0 (0.0)	0 (0.0)	1 (5.0)
Gastrointestinal disorders			
Abdominal discomfort	0 (0.0)	1 (5.0)	0 (0.0)
Abdominal pain	1 (5.0)	0 (0.0)	0 (0.0)
Nausea	0 (0.0)	0 (0.0)	1 (5.0)
Toothache	1 (5.0)	0 (0.0)	0 (0.0)
Vomiting	0 (0.0)	0 (0.0)	2 (10.0)
General disorders and administration site conditions			
Feeling cold	0 (0.0)	0 (0.0)	1 (5.0)
Injection site bruising	0 (0.0)	0 (0.0)	1 (5.0)
Injection site erythema	0 (0.0)	0 (0.0)	1 (5.0)
Injection site warmth	0 (0.0)	0 (0.0)	1 (5.0)
Swelling	0 (0.0)	0 (0.0)	1 (5.0)
Infections and infestations			
Oral herpes	1 (5.0)	0 (0.0)	0 (0.0)
Injury, poisoning and procedural complications			
Joint injury	0 (0.0)	1 (5.0)	0 (0.0)
Scratch	0 (0.0)	1 (5.0)	0 (0.0)
Wound	0 (0.0)	1 (5.0)	0 (0.0)
Investigations			
Aspartate aminotransferase increased	0 (0.0)	0 (0.0)	1 (5.0)
Blood cholesterol increased	1 (5.0)	0 (0.0)	0 (0.0)
Blood creatine phosphokinase increased	0 (0.0)	0 (0.0)	2 (10.0)
Musculoskeletal and connective tissue disorders			
Back pain	0 (0.0)	0 (0.0)	1 (5.0)
Muscle spasms	0 (0.0)	0 (0.0)	1 (5.0)
Nervous system disorders			
Headache	0 (0.0)	0 (0.0)	1 (5.0)
Presyncope	2 (10.0)	0 (0.0)	0 (0.0)
Taste disorder	0 (0.0)	0 (0.0)	1 (5.0)
Psychiatric disorders			
Insomnia	0 (0.0)	0 (0.0)	1 (5.0)
Respiratory, thoracic and mediastinal disorders			
Oropharyngeal pain	0 (0.0)	0 (0.0)	2 (10.0)

Adverse Event SOC/PT	COVLP 15 ug unadjuvanted (N=20)	COVLP 15 ug with CpG 1018 (N=20)	COVLP 15 ug with AS03 (N=20)
Rhinorrhoea	0 (0.0)	1 (5.0)	0 (0.0)
Skin and subcutaneous tissue disorders			
Dyshidrotic eczema	1 (5.0)	0 (0.0)	0 (0.0)
Vascular disorders			
Hot flush	0 (0.0)	1 (5.0)	0 (0.0)

Supplementary Figure 1 Consort Flow Diagram



*One subject did not receive the second vaccination following Grade 3 adverse event but accepted to have blood collection for immunogenicity.

Detailed Immunogenicity Results

Supplementary Table 10 CoVLP-induced Binding Antibody IgG Titers (Anti-Spike ELISA)

Vaccine Group (Dose and Adjuvant)	CoVLP 3.75 µg			CoVLP 7.50 µg			CoVLP 15 µg			Convalescent Serum
	-	+ CpG 1018	+ AS03	-	+ CpG 1018	+ AS03	-	+ CpG 1018	+ AS03	
Day 0										
N	20	20	20	20	20	20	20	20	20	Overall
GMT (95% CI)	61.5 (48.1, 78.6)	56.6 (44.3, 72.4)	64.8 (50.7, 82.8)	50.0 (39.1, 63.9)	55.9 (43.8, 71.4)	55.1 (43.1, 70.5)	60.2 (47.1, 77.0)	52.7 (41.2, 67.3)	60.9 (47.6, 77.8)	N=35 GMT: 19841 (8407, 46825)
Day 21										
N	20	20	20	20	20	20	20	19	20	Mild:
GMT (95% CI)	75.1 (45.4, 124.4)	220.8 (133.4, 365.6)	4354.0 (2629.5, 7209.7)	54.4 (32.8, 90.0)	305.7 (184.6, 506.3)	4550.3 (2748.0, 7534.7)	93.0 (56.2, 154.0)	673.9 (401.7, 1130.6)	3464.3 (2092.2, 5736.4)	N=16 GMT: 11638 (2465, 54952)
GMFR (95% CI)	1.29 (0.78, 2.14)	3.86 (2.33, 6.38)	73.99 (44.67, 122.56)	0.97 (0.59, 1.62)	5.36 (3.24, 8.86)	79.93 (48.31, 132.23)	1.6 (0.97, 2.66)	11.94 (7.12, 20.03)	59.63 (36.04, 98.67)	Moderate: N=8 GMT: 14989 (1617, 138966)
Day 42										
N	20	20	19	20	19	20	20	19	20	Severe:
GMT (95% CI)	496.1 (232.3, 1059.6)	11544.6 (5405.2, 24657.5)	295239.6 (137967.3, 631790.4)	471.0 (220.5, 1005.9)	20811.1 (9553.6, 45334.1)	342989.1 (160587.7, 732568.5)	711.5 (333.1, 1519.6)	22598.3 (10374.0, 49227.2)	173457.2 (81212.8, 370476.3)	N=11 GMT: 52857 (20556, 13)
GMFR (95% CI)	8.45 (3.96, 18.04)	201.85 (94.65, 430.44)	4943.72 (2307.32, 10592.56)	8.56 (4.0, 18.3)	364.73 (167.7, 793.25)	6046.89 (2835.03, 12897.54)	12.21 (5.72, 26.04)	403.77 (185.48, 878.98)	2965.83 (1390.17, 6327.40)	

GMT = Geometric Mean Titer; GMFR = Geometric mean Fold Rise; CI = Confidence Interval

Supplementary Table 11 CoVLP-induced Neutralization Antibody (Nab) Titers (Pseudovirion Neutralization Assay)

Vaccine Group (Dose and Adjuvant)	CoVLP 3.75 µg			CoVLP 7.50 µg			CoVLP 15 µg			Convalescent Serum
	-	+ CpG 1018	+ AS03	-	+ CpG 1018	+ AS03	-	+ CpG 1018	+ AS03	
Day 0										
N	20	20	20	20	20	20	20	20	20	
GMT (95% CI)	5.0 (5.0, 5.0)	5.0 (5.0, 5.0)	5.0 (5.0, 5.0)	5.0 (5.0, 5.0)	5.0 (5.0, 5.0)	5.0 (5.0, 5.0)	5.0 (5.0, 5.0)	5.0 (5.0, 5.0)	5.0 (5.0, 5.0)	
Day 21										
N	20	20	20	20	19	19	19	18	20	Overall N=24 GMT: 86.14 (42.0, 176.7)
GMT (95% CI)	5.0 (3.2-7.7)	5.4 (3.5-8.3)	41.6 (27.0, 64.1)	5.0 (3.2, 7.7)	5.7 (3.6, 8.8)	37.8 (24.3, 58.9)	5.0 (3.2, 7.8)	5.5 (3.5, 8.7)	23.6 (15.3, 36.4)	
GMFR (95% CI)	1.00 (0.65, 1.54)	1.07 (0.70, 1.65)	8.33 (5.41, 12.82)	1.0 (0.65, 1.54)	1.13 (0.73, 1.77)	7.57 (4.86, 11.78)	1.0 (0.64, 1.56)	1.1 (0.7, 1.73)	4.72 (3.07, 7.27)	
SCR (%) (95%CI)	0 (0.0%) (0.0, 16.8)	0 (0.0%) (0.0, 16.8)	12 (60.0%) (36.1, 80.9)	0 (0.0%) (0.0, 16.8)	1 (5.3%) (0.1, 26.0)	8 (42.1%) (20.3, 66.5)	0 (0.0%) (0.0, 17.6)	0 (0.0%) (0.0, 18.5)	9 (45.0%) (23.1, 68.5)	
Day 42										
N	20	19	18	20	19	19	20	16	20	Moderate: N=8 GMT: 77.2 (21.1, 283.1)
GMT (95% CI)	7.9 (4.5-13.7)	71.3 (40.4, 125.9)	2118.3 (1228.7, 3651.9)	9.8 (5.7, 17.1)	112.2 (63.6, 198.0)	1883.8 (1082.9, 3277.0)	11.2 (6.4, 19.4)	118.1 (63.6, 219.4)	1200.9 (690.3, 2089.0)	
GMFR (95% CI)	1.57 (0.90, 2.74)	14.26 (8.08, 25.17)	423.66 (245.75, 730.39)	1.97 (1.13, 3.42)	22.44 (12.71, 39.60)	376.76 (216.58, 655.39)	2.23 (1.28, 3.88)	23.62 (12.72, 43.87)	240.18 (138.07, 417.81)	
SCR (%) (95%CI)	2 (10.0%) (1.2, 31.7)	12 (63.2%) (38.4, 83.7)	18 (100%) (81.5, 100)	4 (20.0%) (5.7, 43.7)	14 (73.7%) (48.8, 90.9)	20 (100.0%) (83.2, 100.0)	5 (25.0%) (8.7, 49.1)	12 (75.0%) (47.6, 92.7)	20 (100.0%) (83.2, 100.0)	

GMT = Geometric Mean Titer; GMFR = Geometric mean Fold Rise; SCR = Seroconversion ratio; CI = Confidence Interval

Supplementary Table 12 CoVLP-induced Neutralization Antibody (Nab) Titers (Live Wild-Type Virus Neutralization Assay)

	Vaccine Group (Dose and Adjuvant)	CoVLP 3.75 µg			CoVLP 7.50 µg			CoVLP 15 µg		
		-	+ CpG 1018	+ AS03	-	+ CpG 1018	+ AS03	-	+ CpG 1018	+ AS03
Day 0										
	N	20	20	20	20	20	20	20	20	20
	GMT (95% CI)	5.2 (4.8, 5.6)	5.2 (4.8, 5.6)	5.0 (5.0, 5.0)	5.5 (4.9, 6.2)	5.2 (4.8, 5.6)	5.4 (4.9, 5.9)	5.2 (4.8, 5.6)	5.2 (4.8, 5.6)	5.4 (4.6, 6.2)
Day 21										
	N	20	20	20	20	20	20	19	20	20
	GMT (95% CI)	5.5 (4.7, 6.5)	6.8 (5.2, 8.9)	29.3 (17.3, 49.7)	6.2 (4.6, 8.3)	6.8 (5.2, 8.9)	29.8 (16.9, 52.7)	5.4 (4.9, 5.9)	6.6 (5.2, 8.4)	21.1 (11.6, 38.4)
	GMFR (95% CI)	1.1 (0.9-1.3)	1.3 (1.0, 1.7)	5.9 (3.5, 9.9)	1.1 (0.9, 1.4)	6.8 (5.2, 8.9)	29.8 (16.9, 52.7)	1.3 (1.0, 1.7)	1.3 (1.0, 1.6)	3.9 (2.0, 7.6)
	SCR (%) (95%CI)	1 (5.0%) (0.1, 24.9)	2 (10.0%) (1.2, 31.7)	15 (75.0%) (50.9, 91.3)	1 (5.0%) (0.1, 24.9)	2 (10.0%) (1.2, 31.7)	13 (65.0%) (40.8, 84.6)	0 (0.0%) (0.0, 16.8)	2 (10.5%) (1.3, 33.1)	11 (55.0%) (31.5, 76.9)
Day 42										
	N	20	20	19	20	20	20	20	18	20
	GMT (95% CI)	7.2 (5.3, 9.7)	56.6 (26.8-119.5)	811.3 (496.0-1327)	27.3 (13.1, 57.2)	157.3 (84.3, 293.4)	1325 (962.6, 1824)	33.6 (14.7, 77.1)	156.9 (74.6, 330.3)	937.0 (592.4, 1482)
	GMFR (95% CI)	1.4 (1.0, 1.9)	10.9 (5.1, 23.5)	162.3 (99.2, 265.4)	4.9 (2.4, 10.1)	157.3 (84.3, 293.4)	247.3 (182.9, 334.4)	6.5 (2.9, 14.8)	30.2 (14.6, 62.6)	174.9 (104.4, 292.7)
	SCR (%) (95%CI)	4 (20.0%) (5.7, 43.7)	14 (70.0%) (45.7, 88.1)	19 (100.0%) (82.4, 100)	11 (55.5%) (31.5, 76.9)	20 (100.0%) (83.2, 100.0)	20 (100.0%) (83.2, 100.0)	12 (60.0%) (36.1, 80.9)	17 (94.4%) (72.7, 99.9)	20 (100.0%) (83.2, 100.0)

GMT = Geometric Mean Titer; GMFR = Geometric mean Fold Rise; SCR = Seroconversion ratio; CI = Confidence Interval.

Supplementary Table 13 CoVLP-induced IFN γ Cellular Response (ELISpot)

Vaccine Group (Dose and Adjuvant)	CoVLP 3.75 μ g				CoVLP 7.50 μ g			CoVLP 15 μ g	
	-	+ CpG 1018	+ AS03	-	+ CpG 1018	+ AS03	-	+ CpG 1018	+ AS03
Day 0									
N	157 (<i>day 0 samples treated as a single group</i>)								
GMT (95% CI)	0.0 (0.0, 1.0)								
Day 21									
N	18	17	19	20	20	18	19	17	18
M SFU (95% CI)	0.0 (0.0 - 3.0)	5.0 (0.0- 39.0)	88.0 (51.0- 233.0)	6.5 (0.0- 21.0)	22.5 (13.0- 57.0)	59.0 (0.0- 175.0)	22.0 (0.0- 168.0)	17.0 (0.0- 44.0)	72.5 (4.0- 151.0)
Day 42									
N	20	20	19	18	19	19	20	18	20
M SFU (95% CI)	8.5 (0.0- 49.0)	49.0 (25.0- 88.0)	628.0 (476.0, 862.0)	21.0 (3.0- 45.0)	61.0 (28.0- 100.0)	305.0 (160.0- 623.0)	24.0 (2.0- 108.0)	61.0 (34.0- 174.0)	281.5 (167.0- 407.0)

M SFU = Median Spot Forming Units per 10⁶ cells; CI = Confidence Interval.

Supplementary Table 14 CoVLP-induced IL4 Cellular Response (ELISpot)

Vaccine Group (Dose and Adjuvant)	CoVLP 3.75 µg				CoVLP 7.50 µg			CoVLP 15 µg	
	-	+ CpG 1018	+ AS03	-	+ CpG 1018	+ AS03	-	+ CpG 1018	+ AS03
Day 0									
N	137 (<i>day 0 samples treated as a single group</i>)								
GMT (95% CI)	0.0 (0.0, 0.0)								
Day 21									
N	16	18	17	17	19	18	17	17	18
M SFU (95% CI)	0.0 (0.0-1.0)	2.0 (1.0-4.0)	37.0 (10.0-42.0)	0 (0.0- 0.0)	2.0 (0.0-3.0)	29.0 (9.0-63.0)	0.0 (0.0-1.0)	0.0 (0.0-1.0)	25.0 (14.0-60.0)
Day 42									
N	19	20	19	18	19	19	18	19	20
M SFU (95% CI)	12.0 (7.0-86.0)	4.0 (2.0-9.0)	445.0 (343.0, 680.0)	6.5 (1.0-28.0)	2.0 (0.0-10.0)	291.0 (200.0-358.0)	9.0 (2.0-23.0)	3.0 (2.0-13.0)	287.5 (224.0-348.0)

M SFU = Median Spot Forming Units per 10⁶ cells; CI = Confidence Interval.

Supplementary References

1. Law B, Sturkenboom M. Safety platform for emergency vaccines (SPEAC). D2.3 Priority list of adverse events of special interest: COVID-19. Report v1.1. 2020 Mar 5.
2. Law B, Sturkenboom M. Safety platform for emergency vaccines (SPEAC). D2.3 Priority list of adverse events of special interest: COVID-19. Report v2.0. 2020a May 25.